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Abstract 
Quantitative imaging with 18F-FDG PET/CT has the potential to provide 
an in vivo assessment of response to radiotherapy (RT).  However, comparing 
tissue tracer uptake in longitudinal studies is often confounded by variations in 
patient setup and potential treatment induced gross anatomic changes.  These 
variations make true response monitoring for the same anatomic volume a 
challenge, not only for tumors, but also for normal organs-at-risk (OAR).  The 
central hypothesis of this study is that more accurate image registration will lead 
to improved quantitation of tissue response to RT with 18F-FDG PET/CT.  
Employing an in-house developed “demons” based deformable image 
registration algorithm, pre-RT tumor and parotid gland volumes can be more 
accurately mapped to serial functional images.  To test the hypothesis, specific 
aim 1 was designed to analyze whether deformably mapping tumor volumes 
rather than aligning to bony structures leads to superior tumor response 
assessment.  We found that deformable mapping of the most metabolically avid 
regions improved response prediction (P<0.05).  The positive predictive power 
for residual disease was 63% compared to 50% for contrast enhanced post-RT 
CT.  Specific aim 2 was designed to use parotid gland standardized uptake 
value (SUV) as an objective imaging biomarker for salivary toxicity.  We found 
that relative change in parotid gland SUV correlated strongly with salivary 
toxicity as defined by the RTOG/EORTC late effects analytic scale (Spearman’s 
ρ = -0.96, P<0.01).  Finally, the goal of specific aim 3 was to create a 
phenomenological dose-SUV response model for the human parotid glands.  
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Utilizing only baseline metabolic function and the planned dose distribution, 
predicting parotid SUV change or salivary toxicity, based upon specific aim 2, 
became possible.  We found that the predicted and observed parotid SUV 
relative changes were significantly correlated (Spearman’s ρ = 0.94, P<0.01).  
The application of deformable image registration to quantitative treatment 
response monitoring with 18F-FDG PET/CT could have a profound impact on 
patient management.  Accurate and early identification of residual disease may 
allow for more timely intervention, while the ability to quantify and predict toxicity 
of normal OAR might permit individualized refinement of radiation treatment plan 
designs. 
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 “It was an act of desperation.  For six years I had struggled with the blackbody 
theory.  I knew the problem was fundamental and I knew the answer.  I had to 
find a theoretical explanation at any cost…” 
 
-Max Planck 
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Chapter 1 
 
Introduction 
 
Implementation of anatomic imaging modalities, like computed 
tomography (CT), has found extensive use in the oncologic setting.  From initial 
staging, to treatment planning, to assessing treatment response, CT is 
ubiquitous [1-4].  In 2000, Therase et al. presented the results of a multi-
institutional collaborative effort to evaluate the existing criteria for treatment 
response in solid tumors set forth by the World Health Organization (WHO) in 
the 1970s [5].  The new guidelines specified the preferred use of imaging 
techniques over clinical evaluation to establish response in solid tumors based 
upon visible reduction in the size of the tumor.  The criteria established that for 
measurable tumors, ≥ 10 mm in at least one dimension, the complete 
disappearance of all target lesions is a complete response, a 30% reduction in 
the longest diameter of target lesions is a partial response, and a 20% increase 
in the longest diameter of the target lesion is deemed progressive disease.  
Stable disease is defined as having insufficient shrinkage or enlargement to 
classify as partial response or progressive disease, respectively.   
However, lesion measurement with anatomic imaging modalities has 
been shown to be a poor prognostic tool for response to therapy [6-11].  In one 
study by Jones et al., 56% of patients had incorrect CT-based T-staging when 
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compared to surgically resected specimens [3].  For regional metastases, 
decreases in the largest axial dimensions of lymph nodes calculated from CT 
images were not found to be a significant predictor of positive surgical 
specimens [7].  These difficulties are not limited to CT imaging. While magnetic 
resonance imaging (MRI) may have superior soft tissue contrast, previous 
studies have demonstrated similarly poor results in predicting tumor response 
[6].  One of the major obstacles in predicting response to treatment with 
anatomic modalities is differentiating residual disease from necrosis or 
surrounding normal tissue.  However, it is expected that imaging functional 
change in target tissues, which often precedes visible anatomic change, may 
improve outcome prediction [12, 13].   
Functional Response Monitoring 
 In recent years, positron emission tomography (PET) using the 
radiolabeled glucose analog, Fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG), 
has gained favor in the oncology setting [14-18].  Exploiting an increased 
reliance on glycolysis for energy production, the preferential uptake of 18F-FDG 
by malignant tissue provides excellent tumor to background contrast.  Multiple 
studies have demonstrated the superiority of PET in the staging of cancers over 
anatomic based modalities [19].  Sensitivities and specificities found in the 
literature range from 84% to 86% and 88% to 93%, respectively.  With the 
development of integrated PET/CT systems, inherently co-registered functional 
and anatomic images have further improved the usefulness of this modality [9].  
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Veit-Haibach et al. assessed the accuracy of PET, CT, and PET/CT in staging 
head and neck cancers and found integrated PET/CT to be significantly more 
accurate in overall TNM staging [20].   
The concentration of radiolabeled tracers can be assessed in two general 
ways:  qualitative and quantitative.  In qualitative assessment the experienced 
nuclear medicine physician compares the intensity and distribution of FDG to 
normal surrounding tissues, like the liver, in order to classify patients as being 
PET positive or negative.  However, this method can be limited by equivocal 
FDG-uptake[21].  
The second method of assessment is quantitative.  Uptake of FDG into 
cancer cells is directly related to the number of viable cells [22].  Therefore, 
calculation of uptake reduction should be a surrogate of tumor cell killing.  The 
net rate of 18F-FDG trapped within the cell can be calculated through graphical 
analysis using the Patlak-Gjedde plot.  Utilizing the following equation, 
 
 
where, c(t) is the activity concentration measured by the imaging system at time 
t, cp(t) is the activity concentration in the plasma, Ki is the rate of activity transfer 
into tissue, and  λ*cp(t) is non-trapped FDG in tissue a plot of the area under the 
time activity curve versus the activity concentration in the tissue with a slope 
equal to Ki can be found with simple linear regression analysis [23].  This 
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analysis is often simplified and activity concentration can be quantified with the 
standardized uptake value (SUV) [20].  The SUV is a simplified version of the 
equation used in the Patlak-Gjedde analysis.  The basic assumption is that if the 
imaging time point is sufficiently far from the injection time point the activity 
concentration will be linearly correlated with FDG trapped in the tissue.  The time 
activity curve is assumed to be proportional to the injected dose normalized by 
some factor describing the distribution of activity in the patient.  One common 
normalization factor is patient mass [24].  The concentration of FDG in the 
plasma at this late time point is expected to be very low, i.e., λ*cp(t) is assumed 
to be zero.   The SUV can then be computed using the following relation, 
    
   
 
where Qi represents the concentration of radiotracer in the tumor or tissue of 
interest, Qinjected is the injected activity, and W is the patient weight in kilograms 
[24].  The SUV has been shown to correlate well with more intensive methods of 
calculating tissue activity concentration [25]. 
Effects of Anatomic Deformation and Patient Set-up Variation 
Comparing the same anatomic volume on serial imaging studies is 
challenging due to two main factors:  treatment induced anatomic changes and 
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patient setup variation.  Considering the former, multiple studies have 
demonstrated the potential anatomic variation in head and neck cancer patients 
resulting from treatment induced tumor and nodal contraction and weight loss.  
Barker et al. utilized daily CT imaging of head and neck cancer patients with an 
integrated CT-linear accelerator system and found the gross tumor volume 
(GTV) decreases at a median rate of 1.8% per treatment day culminating in a 
total loss of 70% of the initial volume.  The center of mass had shifted position 
asymmetrically by a median of 3.3 mm.  For the parotid glands, the median 
volume was found to decrease 0.19 cm3 per day with a median medial shift of 
3.1 mm that correlated with weight loss.  In figure 1.1, an extreme example of 
treatment induced anatomic change and patient setup variation is illustrated.  
Previous response monitoring studies have largely ignored the effects of 
anatomic and patient setup variation.  By utilizing SUVMAX, the maximum pixel 
value in an FDG-avid region, to sample tumor burden, the vast majority of 
investigators were able to avoid the need to accurately map baseline volumes to 
post-RT imaging studies.  However, SUVMAX is not an optimal metric because of 
its strong dependence on noise.  In studies where region based analysis was 
employed, the solution to anatomic and setup variation is usually rigid 
registration.  However, as depicted in figure 1.1 d), rigid alignment of the GTV 
and parotid contours on post-RT studies appears to be entirely inadequate.  The 
rigidly aligned contours extend beyond the patient’s anatomy and contain 
undesired tissue types, as can be seen for the right parotid contour in figure 1 d).  
The main goal of this project is to improve quantitation in treatment response 
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monitoring with 18F-FDG PET/CT.  To achieve this goal we will combine 
advanced image registration techniques with RT treatment designs and serial 
functional images.   
Tumor Response 
The potential of PET/CT to improve treatment response monitoring in cancer 
patients has been noted for some time.  In one early study from 1994, Greven et 
al. found that 6 of 7 head and neck cancer patients with increasing FDG 
accumulation following RT were positive for persistent disease, while all 
responding patients were found to have decreases in tracer uptake [26].  Since 
this initial study multiple reports have investigated 18F-FDG PET/CT to determine 
its effectiveness in response monitoring [19].  Studies by Allal et al., Kitagawa et 
al., and Kao et al. found that SUVMean performed well as a predictor for local 
control in head and neck cancers [27-29].  One recent study by Yao et al. 
demonstrated the high negative predictive value of SUV in response monitoring 
studies (roughly 99%) [30]. In contrast, studies by Arslan et al., Yen et al., and a 
follow-up by Greven et al. found quantitative measurement of FDG-uptake not to 
be useful in response monitoring [31-33].   
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a) b) 
c) d) 
 
Figure 1.1 Extreme anatomic and setup variation 
An extreme example of setup and anatomic variation possible in response 
monitoring studies between pre-RT CT (a and c) and the post-RT CT (b and d) 
imaging studies.  Axial views are presented with parotid (orange) and gross 
tumor volume contours (maroon) as originally contoured on the planning CT 
images and rigidly aligned to the C2 vertebra. 
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A recent study by Moeller et al. found that while SUV was significantly different 
between responding and non-responding patients, it offered no improvement 
over conventional CT in positive (58% vs. 50%) and negative predictive values 
(96% vs. 97%) and little improvement in positive predictive value (57% vs. 50%)  
[34].  These examples illustrate that quantitative treatment response monitoring 
with PET/CT has yet to live up to its initial promise. 
While many studies have supported the overall philosophy behind PET 
imaging of tumor response, namely that reduced uptake of 18F-FDG generally 
corresponds to better prognosis for patients, questions still remain.  Consider the 
issue of sampling FDG-uptake on PET images.  By far the most popular metric 
to assess tumors has been SUVMax.  The justification frequently cited for its use 
is that the term represents the maximum tumor burden.  However, SUVMax is 
known to be strongly affected by image noise.  In studies by Boellard et al. and 
Falen et al., SUVMax variations in excess of 50% were observed [35, 36].  
Alternatively, region-of-interest (ROI) based analysis may be used to determine 
an average tissue uptake.  With volume based techniques, the question then 
arises of whether automated or manually defined regions should be utilized.  
More recently, SUVPeak has been suggested as metric to assess tumor viability.  
SUVPeak is defined as an approximately 1 cm3 volume centered on the maximum 
pixel value [37]. In light of expected anatomic changes discussed earlier, 
recommendations to compare the same volume on serial imaging studies 
present profound challenges [38]. 
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Normal Tissue Response 
Treatment of head and neck cancer often results in the salivary glands 
receiving high mean doses of radiation (28 to 45 Gy) [39].  Irradiation of the 
parotids can lead to reduced salivary flow and the subjective assessment of dry 
mouth, called xerostomia [40, 41].  Xerostomia is the primary morbidity 
associated with RT for head and neck cancers with 65% of patients reporting 
severe to moderate xerostomia after one year [40].  Saliva produced by the 
major and minor salivary glands plays a vital role in mastication, speaking, and 
the mucosal immune system with the parotid glands producing the majority of 
the salivary volume (approximately 60%).  Salivary flow reduction can affect not 
only quality of life (QOL), but lead to oral fissures, infection, and potential 
malnutrition [40].  Salivary function is typically evaluated with patient self-
reported QOL questionnaires to gauge the severity of xerostomia, or 
measurement of saliva volume [42].  However, these techniques often perform 
poorly and have large variations.    
   Imaging salivary gland function offers a non-invasive method to assess 
radiation induced damage.  Salivary gland scintigraphy (SGS) is one method 
that has been utilized to image salivary function by measuring the concentration 
of 99mTc-pertechnetate remaining in the glands following the administration of a 
salivation inducing agent [43].  Previous reports assessing function after RT 
have found good correlations between activity concentrations measured with 
scintigraphy and saliva volume [44].  Recently, SGS has been used to perform 
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dose-response analysis in the parotid glands [45, 46].  However, these 
techniques were limited to 2D planar images of the salivary glands without any 
inherently aligned anatomic images.  Given the parotid gland shrinkage and 
medial shifting discussed above, automatic alignment of pre-RT volumes is 
desirable.  With the increasing use of 18F-FDG PET/CT in initial staging and 
follow-up for head and neck cancers, incidental collection of parotid uptake may 
prove to be a readily accessible alternative to additional nuclear medicine 
studies or salivary flow measurements.   
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Central Hypothesis 
 We hypothesize that more accurate image registration will lead to 
improved quantitation of tissue response to radiotherapy with 18F-FDG PET/CT 
imaging.  
Specific aim 1 
To apply deformable image registration techniques to images acquired during a 
prospective clinical trial designed to assess and predict RT outcomes with 18F-
FDG PET/CT.  
Working Hypothesis:
Specific aim 2.a  
  Voxel-by-voxel mapping of primary tumor volumes to 
serial 18F-FDG PET/CT scans will significantly improve region based quantitative 
tumor response analysis.   
Evaluate the potential to determine normal organ-at-risk (OAR) toxicity in 
patients treated with intensity modulated radiotherapy (IMRT) for head and neck 
cancers with 18F-FDG PET/CT. 
Working Hypothesis:
 
  Relative change in parotid gland uptake of 18F-FDG will 
function as an objective imaging biomarker of oral complication following RT. 
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Specific aim 2.b  
To quantify and model the planned-dose-functional-response relationship of the 
parotid glands in head and neck cancer patients treated with IMRT. 
Working Hypothesis:  A predicted imaging biomarker for oral complication 
following RT will correlate closely with whole mouth stimulated salivary flow.   
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Chapter 2 
Radiotherapy and the Head and Neck 
 
Cancers of the Head and Neck 
 Head and neck cancers make up roughly 6% of all cancers diagnosed in 
the United States.  This corresponds to 46,000 patients suffering from a cancer 
originating in the head and neck region each year.  An estimated 11,000 
individuals will die from this disease in the US.  Worldwide, over 600,000 
patients will be diagnosed with 350,000  deaths.  The majority of these cancers 
arise in the epithelial cells that form the protective linings of cavities and are 
known as squamous cell carcinomas [47].  This makes alcohol and tobacco 
consumption significant risk factors for this histology [48].  Additional risk factors 
include human papilloma virus (HPV) infection, poor oral hygiene, wood dust 
inhalation, and asbestos to name a few.  The primary disease sites of the head 
and neck regions are the nasopharynx, oropharynx, hypopharynx, and larynx.  
Among males, cancers of the pyriform sinus, in the hypopharynx, contribute the 
most patients per 100,000 (2.33) in the US. In females, cancers at this site also 
supply the most patients (1.67).   
Treatment of Head & Neck Cancers 
 The majority of patients with head and neck cancers present with 
advanced disease (Stage III and IV), with only about 1/3 presenting with early 
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stage disease [48].  Although staging varies between sites, primary advanced-
stage tumors in the head and neck are typically approximately 4 cm in size as 
defined by the American Joint Commission on Cancer (AJCC).  Typical 
treatment strategies for late stage disease are surgery, radiation, and 
chemotherapy.  Progression free survival rates seen for all cancers of the oral 
cavity, oropharynx, hypopharynx, and larynx are 36% at five years with overall 
survival rates of approximately 40% [49-51]. The concurrent delivery of 
chemotherapeutic agents like cisplatin can improve 5-year disease free survival 
to 47% with overall survival rates of 53% [50].  Intensity modulated radiation 
therapy (IMRT) has shown promising results in terms of locoregional control 
94%, but acute toxicity results have not been favorable [52, 53].  Typical 
treatments for head and neck cancers consist of cumulative doses of 63 – 70 Gy 
given in 30 – 35 fractions of 1.8 – 2.2 Gy 5 days/week.  Alternative fractionations 
schedules have also led to improvements in 5-year disease free survival.  
Hyperfractionation regimens have been shown to offer 8% absolute benefit.  
Phase III clinical trials have led to recurrence rates within the first two years of at 
least 50% [54, 55].  Treatment following failure is often salvage surgery or 
systematic therapy with methotrexate [56].  Another option that has led to 
improvement in progression free survival is re-irradiation.  With the recurrence 
rates seen in this patient population early identification of residual disease is 
critical for patient management and the use of additional therapies.         
 Because of the complex anatomy in the head and neck region normal 
tissue complications are common.  Loss of taste, dysphagia, dental carries, and 
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hearing loss are common symptoms [57].  One of the more frequent morbidities 
is radiation-induced xerostomia. Up to 65% of patients will report oral dryness 
one year after treatment [40].  Prevention strategies do exist, but the high doses 
delivered make damage to the salivary glands a significant issue. 
The Human Salivary System 
 Saliva is a vital body fluid.  It performs crucial roles in mastication, 
digestion, swallowing, oral fauna regulation, and speech.  Saliva is composed of 
approximately 99% water.  Other constituents include, but are not limited to, 
lipids, amino acids, and proteins.  The protein components consist primarily of α-
amylase (30%) which begins the digestion of polysaccharides.  Additionally, 
saliva provides an excretory route for metabolic waste products like urea.  The 
secretory function of the salivary glands is controlled by the autonomic nervous 
system.  Saliva production can be stimulated through taste, smell, chewing, or 
exogenous stimulants [41].   
 Saliva is produced primarily in three paired organs in the upper 
aerodigestive tract.  However, there are multiple minor salivary glands 
distributed throughout the buccal cavity.  The number and arrangement will vary 
among patients.  The three major paired glands are:  the parotid, submandibular, 
and sublingual glands.  The major salivary glands produce over a liter of saliva 
per day [58].  The parotid glands can produce anywhere from roughly half of the 
salivary volume up to 70% of the total volume.  However, saliva produced in the 
parotid glands is primarily created during stimulation.  In unstimulated 
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conditions, the contribution is much smaller with the submandibular glands 
taking the dominant role, producing as much as 80% of the saliva volume.   The 
sublingual glands are typically responsible for 2 -5% of the saliva produced [59-
61].  
 The major salivary glands have a well defined structure.  The organs 
consist of ducts, myoepithelial cells, connective tissue, and the saliva producing 
unit, the acini.  The acinar cells may be either mucous or serous exocrine cells.  
The acinar cells are contained in many spherical clusters throughout the glands.  
Radiating across the acinar cell, the processes of myoepithelial cells embrace 
the acinar cell and contract to force saliva into the collecting ducts.  The 
myoepithelial cells comprise about 1.6% of the volume of the parotid glands [60].  
Saliva moves through the secondary ductile system and into the intraglandular 
main duct.  In the case of the parotid glands, the saliva then traverses the 
extraglandular segment of Stensen’s duct which is superficial to the masseter 
muscle before entering the buccal cavity through the orifice of Stensen’s duct.  
The parotid glands contain serous acinar cells, while the submandibular and 
sublingual glands contain both serous and mucous acinar cells.  Qualitatively, 
the saliva produced in the submandibular and sublingual glands is thick and 
sticky, with the parotids producing a watery product.  
 Salivary function can be diminished by many factors e.g., pathologic 
sources like Sjogren’s syndrome or through damage induced by ionizing 
radiation.  Patients receiving radiation therapy for head and neck cancers will 
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routinely experience high doses to the salivary glands.  However, decreases in 
salivary flow are detectable in as little as 24 hours after doses as small as 2 Gy 
[62].  Within the first week of treatment salivary flow rates can drop by 50% or 
more [63-65].  Salivary flow rates will continue to decline throughout the 
treatment course.  In one study of IMRT designed to spare the salivary glands, 
the contralateral and ipsilateral parotid glands received mean doses of 22 Gy 
and 55 Gy, respectively, whereas mean doses to the ipsilateral submandibular 
gland were on the order of 67 Gy.  Contralateral submandibular glands receive 
mean doses of 58 Gy [42].  No appreciable salivary output was measured for the 
ipsilateral glands.  On the other hand, measured salivary flow for contralateral 
parotid glands decreased initially, but approached pre-RT levels at one year 
post-RT [42].   
 Parotid Radiosensitivity 
The response of salivary gland constituent tissue to ionizing radiation is 
complex and not well understood.  The saliva producing units of the salivary 
glands, acinar cells, are the assumed targets in radiation damage leading to 
reduced salivary flow.  The acinar cells are reverting postmitotic cells.  Cells of 
this type will exhibit little regular division and variable differentiation.  
Consequently, these targets are expected to be relatively less radiosensitive 
than lymphocytes, for instance, and exhibit mostly late effects.   
However, as discussed above reduced salivary flow can be detected in as 
little as 24 hours.  One classic explanation is that radiation induced apoptosis is 
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responsible for the high acute radiosensitivity of the acinar cells, yet studies in 
rhesus monkeys failed to identify appreciable levels of apoptosis [66, 67].  
Additionally, similarly low levels of apoptosis, less than 2%, have been observed 
in rat acinar cells [68].  Further complicating the picture, Roesink et al., using 
salivary gland scintigraphy, observed that while uptake of radiotracer was not 
diminished in the salivary glands, salivary flow was reduced.   
To account for the complicated radiation response observed in the 
salivary glands, hybrid models of radiosensitivity have been proposed.  In one 
model proposed by Konings et al., the acute radiosensitivity was proposed to 
result from radiation damage to the plasma membrane of the secretory cells 
[69].  The proposed model is similar to the indirect action of radiation model that 
results in damage to nuclear DNA.  Briefly, after interaction with a photon, a 
water molecule becomes ionized.  The chemical reaction is, 
 
 
where, H2O+ is the ion radical.  The ion radical has a short lifetime and decays to 
form a free radical, which has an unpaired electron.  The chemical reaction to 
form the hydroxyl radical, OH is, 
 
 
OHOHOHOH +→++ 322
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The highly reactive hydroxyl radical is responsible for much of the damage to 
nuclear DNA.  Damage to the cellular membrane is initiated by a process known 
as lipid peroxidation.  In this reaction, the oxygen radical targets the 
phospholipids that make up the cell membrane.  After removing hydrogen from 
the fatty acid chain, a lipid alkyl radical will be formed.  The lipid alkyl radical 
then reacts with oxygen to form a peroxyl radical.  The peroxyl radical then 
removes a hydroxyl radical from the neighboring fatty acid chain, producing new 
alkyl radicals and inducing a chain reaction.  One of the many effects of 
peroxidation of cellular membrane lipids is the disruption of membrane 
receptors.  The disruption of the cell signaling pathway for saliva secretion is 
hypothesized to be the source of the acute response of the parotid glands to 
ionizing radiation [70].   
The mechanism for late damage is the lack of cell replacement due to the 
loss of progenitor cells.   The progenitor cells in the parotid acini are located at 
the distal segments of the ductile system.  This classic model of late response is 
supported by studies in the rat parotid [71].  Following irradiation with 30 Gy, the 
parotid glandular connective tissue increased from 10% to 60% of the volume.  
The relative number of acinar cells decreased from 80% to 20% of the volume.  
Following these histopathological findings, the salivary flow was reduced by 
90%.   
 Extensive studies have been carried out to assess the functional outcome 
the parotid glands after RT.  In one study from Eisbruch et al., salivary flow 
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measurements were collected from 88 patients at multiple times points up to 1 
year post-RT [42].  Parotid gland response was best described by dose 
thresholds.  Significantly higher unstimulated salivary flow was seen for glands 
receiving a mean whole organ dose less than 24 Gy.  For stimulated flow, 
parotid glands receiving a mean dose less than 26 Gy had significantly better 
function.  Chao et al. observed that the parotid glands lose function 
exponentially with dose.  Specifically, the parotid glands were found to lose 5.4% 
of the stimulated salivary flow at 6 months for every Gy delivered [39].  In 
contrast, Roesink et al. observed parotid gland functional response to be best 
described as linear with no threshold dose [45].  While the exact functional form 
of dose response for parotid gland functional response remains unknown, 
keeping the mean dose to the parotid glands less than or equal to 26 Gy has 
been shown to be a significant predictor of salivary toxicity.  The TD50/5 for the 
parotid glands is 46 Gy [72].   
Assessing Salivary Toxicity 
 Assessing salivary toxicity is accomplished primarily through two 
methods:  objective and subjective.  Objective evaluation may take the form of 
physician assessment based upon the Radiation Therapy and Oncology Group 
(RTOG) and European Organization for Research and Treatment of Cancer 
(EORTC) SOMA scale [73, 74].  Graded 1 – 4, representing increasing severity 
of toxicity, the scale is meant to capture the response of individual organs.  
Another method of objective assessment is measurement of the saliva produced 
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by each of the major glands or from the whole mouth with saliva mixed.  Based 
upon relative changes in the quantity of salvia produced, the EORTC/RTOG 
scale can be utilized to also assign a grade, 1 – 4, to the salivary toxicity.  
Subjective evaluation is primarily carried out through patient self-reported quality 
of life questionnaires [75].  The patient answers a series of questions relating his 
or her difficulty at performing common tasks like speaking or eating as a result of 
dryness.  Each question is ranked on a 1 – 10 Likehart scale and a final 
summary xerostomia qualify of life (XQL) score can be calculated for the 
questionnaire. 
 Each metric has limitations.  Because xerostomia is the perception of dry 
mouth, patient self-reported scores may best reflect the symptoms experienced 
by the patient, but these are fundamentally limited by their subjective nature.  On 
the other hand, XQL scores have been shown to correlate significantly with 
measured salivary flow rates [76].  In the case of physician assessed toxicity, 
salivary flow rates were not found to correlate with xerostomia grade [76].  
Interestingly, physician assessment was found to underestimate the severity of 
toxicity when compared to patient self-reported scores.  Finally, for 
measurements of salivary flow, large normal ranges are often found.  In one 
study by Ship et al., untreated individuals with the lowest and highest 10th 
percentiles of produced saliva mass had similar oral health [77].  Further 
complicating the use of salivary flow are large intra-patient variations that have 
been observed on the order of 50%.  The poor performance of these 
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cumbersome additional procedures coupled with ambiguous endpoints presents 
an opportunity for novel methods to assess salivary toxicity. 
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Chapter 3 
 
Specific Aim 1 
 
To apply deformable image registration techniques to images acquired during a 
clinical trial designed to assess and predict RT outcomes with 18F-FDG PET/CT. 
Working Hypothesis:  Voxel-by-voxel mapping of primary tumor volumes 
to serial 18F-FDG PET/CT images will improve quantitative tumor 
response analysis. 
Purpose: 
 Assessing and predicting the response of tumors to RT has long been the 
goal of PET imaging.  The ability to differentiate responding from non-
responding tumors before response is detectable through measurement of gross 
disease holds great promise.  A question of fundamental importance is whether 
response should be assessed using the total tumor volume or the most 
aggressive regions of the initial tumor.  Once a decision has been made as to 
the appropriate volume to assess response to RT, the question of how to align 
this volume on the subsequent imaging studies must be answered.  To address 
this question, four arms were tested in specific aim 1.   
The first two arms this specific aim attempted illuminate which volume 
delineation method should be preferred for predicting and assessing response to 
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RT with 18F-FDG PET/CT.  Total tumor volumes as well as the most 
metabolically active volumes defined on both PET and CT images were utilized 
to answer this question.  Second, each arm was split into two arms to test the 
preferred alignment technique.  A deformable image registration algorithm and a 
bony alignment method were utilized to align the pre-RT volumes across the 
serial imaging studies.  Early identification of patients not responding to 
treatment may allow for more timely alteration in patient management. 
Methods and Materials: 
Patient Cohort 
Patients were enrolled into an IRB approved protocol (LAB07-0043) at 
The University of Texas MD Anderson Cancer Center (MDACC) designed to 
assess and predict, prospectively, radiotherapy (RT) outcomes using serial 18F-
FDG PET/CT.  Eligible adults had biopsy-proven stage III-IVb (American Joint 
Committee on Cancer) squamous cell carcinoma of the oropharynx, 
hypopharynx, or larynx with scheduled intensity modulated RT (IMRT) or 
chemoradiotherapy.  Between 2005 and 2007, 107 patients were screened for 
enrollment.     
All patients were scheduled for one pre-RT 18F-FDG PET/CT study 
collected within four weeks prior to the beginning of treatment.  Follow-up 
PET/CT studies were performed approximately 8 – 9 weeks after the completion 
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of treatment.  All functional imaging studies were performed with integrated 
PET/CT systems.  
 Initial follow-up was performed eight to nine weeks after the completion of 
treatment.  Follow-up radiographic, clinical, and pathologic evidence served as 
the gold standard for assessing patient outcome.  Patients with no evidence of 
disease clinically or radiographically were continually monitored and considered 
as RT responders.  Patients with residual or recurrent disease at the time of 
follow-up were considered RT non-responders.  
RT and Systemic Treatment 
 Patients screened for inclusion followed two general therapeutic 
pathways.  In one arm, patients received only IMRT; in the second arm, patients 
received concurrent systemic therapy with IMRT.  Treatment plans were created 
with the Pinnacle3 treatment planning system (Philips Medical Systems, 
Andover, MA).  The typical prescription dose was 70 Gy given 5 days a week in 
2.12 Gy fractions.  Other dose prescriptions used for this cohort were 1.8 Gy/fx, 
2.0 Gy/fx, and 2.2 Gy/fx.  Patients were not stratified based upon varying doses 
per fraction.  
Functional Imaging 
 PET imaging studies were performed with the integrated GE Discovery 
(GE Medical Systems, Milwaukee, Wisconsin) PET/CT systems.  Following 
collection all images were transferred to the institutional digital archival system. 
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Patient preparation for F-FDG PET/CT imaging was crucial to establish uniform 
collection conditions of all functional studies.  Patients were instructed to fast for 
at least four hours prior to injection of F-FDG radiotracer.  It is important for 
patients to maintain a high protein-low carbohydrate diet, abstaining from sugary 
drinks, but still maintaining hydration.  Reducing the blood glucose concentration 
will reduce uptake competition between injected FDG and consumed 
carbohydrates.  Prior to imaging, serum glucose levels were measured and 
patients found to have levels greater than 200 mg/dL were not imaged.  Patient 
height (m) and weight (kg) were also recorded.  Imaging subjects were then 
instructed to lie supine and minimize movement to reduce the accumulation of 
FDG in muscle.   
 Tracer was injected intravenously with a 20 – 23 gauge intracatheter.  
Institutional guidelines specify the injection of 5 – 20 mCi of 18F-FDG followed by 
a saline flush of 10 – 20 cm3.  Following injection, procedural recommendations 
specify a 30 – 45 minute waiting period to allow the tracer to be absorbed 
throughout the patient’s tissues.  American College of Radiology Imaging 
Network (ACRIN) guidelines stipulate that imaging should begin within 60 ± 10 
minutes.  Additionally, all follow-up PET/CT studies should match the injection to 
imaging time as closely as possible, varying no more than 10 minutes.    
Anatomic Imaging 
 In addition to PET/CT imaging studies, patients also had contrast 
enhanced CT studies performed.  The first was collected prior to the start of 
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treatment and the follow-up was collected 8 weeks after the completion of 
treatment.  All images were reviewed by a board certified radiologist and 
classified as representing complete, partial, stable, or progressive response [5].  
The interpretation of contrast enhanced CT images was performed without 
knowledge of the PET/CT results.   
Post-Treatment Surveillance 
 Post-RT surveillance followed a well defined pathway.  Initial follow-up 
was scheduled for 8 weeks after the completion of treatment.  Subsequently, 
patients were assessed every 3 – 4 months for the first two years with clinical 
examination and contrast enhanced CT studies of the head and neck.  Patients 
with no evidence of disease were monitored with regularly scheduled visits.   
 Patients with unequivocal incomplete nodal response had unilateral or 
bilateral neck dissection performed.  Equivocal findings were assessed by 
ultrasound-guided fine needle aspiration.  Patients with negative findings were 
followed with regularly scheduled visits.  Additionally, patients with positive 
findings on clinical or radiographic examination for recurrent primary tumors had 
salvage surgical resection performed.   
Pathologic Tissue Assessment  
 A single board certified pathologist performed all step-sectioning and 
evaluation of neck dissection samples.  This methodology is detailed in a 
previous report by Moeller et al [34].  Briefly, nodes measuring greater than 1 cm 
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were bisected along the longest diameter.  Both halves were then sectioned with 
additional levels cut at 150 μm intervals.  If a node measured less than 1 cm, 
one section was obtained with additional levels at 100 μm intervals.  At least one 
subcapsular squamous cell cluster was required for positive metastatic 
involvement.   
Tumor Volume Delineation 
The ability to differentiate responding and non-responding primary tumors 
was investigated for SUV derived in two general methods.  First, the frequently 
utilized SUVMax, the maximum pixel value for the most FDG-avid regions, was 
collected from user defined regions that fully encompassed the most FDG-avid 
tumor regions on pre-RT PET/CT images.  Regions similar in size and anatomic 
relation were drawn on post-RT images for post-therapeutic assessment.  
Next, SUVMean was derived from three volumetric techniques.  First, the 
gross tumor volume (GTV) from the clinically delivered treatment plan was used 
as the ROI.  The GTV volume in head and neck treatments at our institution 
contain both primary tumor and nodes.  However, for the purposes of this 
analysis primary tumor volumes were separated from involved nodes.  GTV 
contours created on planning CT images were used to collect baseline and 
follow-up SUVMean.  Although not created on PET images, the GTV region-of-
interest (ROI) takes advantage of the inherent registration between PET and CT 
images collected with integrated scanner systems.  SUV derived from this metric 
represented a CT defined total tumor volume. 
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Next, a volume defined exclusively on the pre-RT PET images was 
utilized.  The volume was defined with an auto-contouring algorithm created for 
use with the Pinnacle3 treatment planning system.  The source code is given in 
the appendix under PET50Threshold.script.  After the PET images were 
imported into the Pinnacle3 treatment planning system and assigned an 
appropriate primary, CT, image set, the algorithm required the user to define a 
region that fully resolved the most FDG-avid region of the image that is of 
interest.  This contour is denoted as “FindMaxPixel,” in the source code.  Most 
importantly, prior to running the script, the destination contour had the primary 
volume set as the pre-RT PET image.  After running the script, an isocontour 
was created with the name “50Primary.”  This contour encompassed all pixels in 
the FDG-avid region that are 50% of the maximum pixel value or greater.  This 
value was selected because of its frequent use in the literature [36, 78, 79].  The 
contour was then transferred to the corresponding volume on the primary image 
set, in this case the pre-RT CT.  This volume was then deformably mapped, as 
describe above, to post-RT PET/CT images where it was used to collect the 
average SUV.  SUV derived from this metric represented a PET defined total 
tumor volume. 
Finally, SUVPeak for the FDG-avid regions at the site of the primary tumor 
were determined.   SUVPeak is defined as an approximately 1 cm3 volume 
centered on the maximum pixel of an FDG-avid region with a diameter of 1.2 
cm.  Utilizing the script SUVpeak.m, SUVpeak volumes were defined on pre-RT 
PET/CT images.  The approximately 1 cm3 volume was then deformably 
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mapped to post-RT PET/CT images in a procedure analogous to that described 
above.  SUV derived from this metric represented the most metabolically active 
volume.     
SUV values of responding and non-responding patients derived from 
each technique were then compared.  Nonparametric Mann-Whitney rank sum 
tests were used to infer whether the SUV values of responding and non-
responding patients were different.  Pre- and post-RT absolute SUV metrics as 
well as relative change in SUV defined as,  
 
 
were tested.  Statistically significant differences are considered to be those with 
P<0.05. 
Image Registration 
 The alignment of tumor volumes was accomplished with two techniques.  
First, pre-RT tumor volumes were mapped to serial imaging studies with an 
enhanced “demons” algorithm.  Second, pre-RT volumes were registered to 
serial imaging studies with rigid alignment.   
 The first alignment method employed a deformable image registration 
technique [80, 81].  Based upon the “demons” algorithm originally proposed by 
Thirion et al., it is based upon CT image intensity (Hounsfeld units)  [82].  
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Intensity differences between a static and moving image are minimized 
iteratively producing a displacement vector for each voxel.  The displacement 
vector field is then applied to the reference image, effectively deforming or 
mapping voxels from the reference to the target image.  Implementation of a 
multi-resolution approach and the addition of an active force derived from the 
intensity gradient information in the target image, have allowed the enhanced 
“demons” algorithm to greatly improve the registration quality over the original 
implementation.  Wang et al. have shown in mathematical and phantom studies 
the overall registration error of the enhanced “demons” algorithm to be 
approximately 1 mm [81].   
 For the alternate registration technique, a CT-to-CT bony alignment 
algorithm was utilized [83, 84].  By exploiting an ROI defined on the planning CT 
images, the algorithm matches the same image feature in a target image set by 
minimizing a cost function.  The cost function used is the mean absolute 
difference in CT numbers, computed on a voxel-by-voxel basis, between the 
planning and, in this case, either the pre- or post-RT PET/CT.  The ROI used for 
bony alignment was the C2 vertebra.  The C2 vertebra was selected because of 
its proximity to the multiple disease sites for the current cohort.  Additionally, in 
one study by Zhang et al., C2 was found to have the smallest systematic and 
random daily setup variations in the anterior-posterior (AP) and superior-inferior 
(SI) directions, making it a stable alignment point [85].   
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Volume Alignment Workflow 
 The following methodology details the steps required to utilize the CT 
Assisted Targeting for Radiotherapy (CAT) software to collect SUV for a volume 
of interest mapped from a reference image set to a daily image set.  Briefly, the 
methodology involved first contouring the C2 vertebrae for each patient for initial 
rigid alignment.  Second, tumor volumes created within the Pinnacle Treatment 
planning system and MATLAB were deformed, separately, to a daily CT image 
set.  For this particular project, the reference image set was the planning CT 
(PCT) and the daily image sets were the pre- and post-RT PET/CT image sets.  
After all contours were deformed, the SUV and dose were collected from each 
volume of interest.  The output format was a text file with an (x,y,z) voxel 
location within the image volume and a numeric value for the voxel (SUV or 
dose).  The workflow will now be explained in detail and will be of particular 
interest to future investigators using the CAT software for PET/CT research. 
 Prior to any post-processing, all serial image sets were collected.  This 
was accomplished using the ClinicStation software platform.  Within this 
platform, all serial studies were reviewed, selected, and then exported as 
DICOM images to the internet database Evercore.  After the images were 
downloaded from Evercore, folders containing the DICOM images were 
renamed to CT01, CT02, PET01, or PET02 using the scanorder.m script to more 
easily identify the image study chronology.  While created for this specific task 
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the script scanorder.m may be of use to other investigators using multiple image 
sets.  This script is given in the appendix. 
 Next, all patient treatment plans were collected.  Within Philips’ Pinnacle3 
Treatment Planning System (version 7.6c), the axis (C2 vertebrae) was 
contoured for every patient.  The axis was contoured for each patient for initial 
three dimensional bone alignments.  Volumes of interest obtained from the 
original treatment plan included the GTV and PET threshold algorithm.  Although 
not created on the planning CT images, the PET based threshold contour was 
created using the Pinnacle3 treatment planning system.            
  Following the collection of all imaging studies and volumes of interest, 
data were imported into the CAT software workspace.  This includes treatment 
plans and all functional imaging studies.  Within the CAT workspace, the 
reference image (PCT) was first rigidly aligned to the daily image set (pre- or 
post-RT PET/CT).  In the case of the PET-based threshold volume the reference 
image set was actually the pre-RT PET/CT image set, but the workflow was 
identical.  The initial bony alignment utilized the algorithm specified in the 
previous section.  After a global minimum for the cost function was achieved, 
translation shifts in the left/right, anterior/posterior, and superior/inferior were 
applied to the volumes of interest thereby aligning them to the daily image set.  
For the bony alignment arm of this aim, no further registration steps were 
required and SUV was collected for pre- and post-RT PET/CT images.   
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 For the deformable registration arm, additional alignment steps were 
required.  Next, a user-defined deformation volume was selected to completely 
resolve the site of primary tumor with boundaries stopping approximately 
inferiorly at the level of the suprasternal notch and continuing to the most 
superior slice of the PET image set.  The enhanced demons algorithm was then 
utilized to map all voxels within the user defined deformation volume from the 
reference image set to the daily image set.  This resulted in a vector 
displacement field that mapped the reference image (planning CT) separately to 
the daily images (pre- and post-RT PET/CT) images.  Visual inspection was 
utilized to compare the daily image set with the resulting deformed reference 
image set.  The deformable transformations were then applied to the volumes of 
interest in order to map the regions to either the pre- or post-RT PET/CT 
images.  Finally, SUV was collected from the serial PET/CT images using the 
mapped volumes of interest.     
Calculating SUV in the CAT Workspace 
 Tumor glucose use in this work was quantified with SUV normalized to 
total body mass [86].  In order to calculate SUV, the injected dose activity in 
MBq was extracted from the DICOM header and decay corrected to the time of 
imaging by the following relation, 
 
6588
time imaging to Injection
time Imaging 0.5* Dose InjectedDose Injected =
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where the injected doses are in units of MBq and the denominator in the 
exponent is the half life of 18F.  Next, each pixel in the image was multiplied by 
the rescale slope in the DICOM header to account for the restricted maximum 
pixel value of a GE PET image, 32, 7636 Bq/mL.  Finally, the patient mass was 
extracted and SUV was computed according to the following relation, 
 
Additionally, the CAT software platform capability to calculate SUV was 
expanded to include lean body mass and body surface area normalization [87].      
Receiver Operating Characteristic Analysis 
 Receiver operating characteristic (ROC) analyses were performed to 
compare the ability of each metric described above to predict response to RT.  
Classification of patients as normal or abnormal was based upon response to 
RT as determined through pathology and continued clinical surveillance.  
Median follow-up time was approximately two years post-RT.  Software from 
SPSS an IBM Company (Chicago, IL) was utilized to perform ROC analyses.  
The ROC curve is a plot of the true positive fraction, sensitivity, versus the false 
positive fraction, (1 – specificity).  In other words, the sensitivity is the fraction of 
agingtimeseInjectedDo
UV
Im
[g] mass Patient*slope Rescale*[Bq/mL] value PixelS =
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cases that a clinician calls abnormal that are actually abnormal as determined by 
an alternate gold standard.  The specificity is the fraction of cases that a clinician 
calls normal that are actually normal.  After ROC curves were created for all 
SUV metrics utilized, decision thresholds were established based upon 
tabulated data points of each ROC curve.  The point along the ROC curve that 
maximized sensitivity and minimized (1 – specificity) was selected as the 
decision threshold for a particular metric.  In addition to calculating the true 
positive fraction and true negative fraction for each technique (sensitivity and 
specificity), positive and negative predictive values were computed (PPV and 
NPN).  The PPV refers to the probability that a patient is actually abnormal or a 
non-responder when classified as such.  On the other hand, NPV relates to the 
probably that the patient is actually normal or responded to RT when classified 
accordingly.   
Finally, the ability of each metric to discriminate responding and non-
responding patients was compared.  The ROC curve is constructed by 
determining the sensitivity and specificity at various decision threshold values.  
Therefore, the area under the ROC curve (AUC) will depend upon how well the 
metric is able to discriminate responding and non-responding patients and help 
to quantify the usefulness of the metric.  In the case of pure guessing, AUC = 
0.5.  If AUC is less than 0.5, the metric performs worse than guessing.  Software 
from MedCalc (Mariakerke, Belgium) was used to perform non-parametric tests 
to compare the AUC for each metric [88].  Statistically significant differences are 
considered to be those with P<0.05. 
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Results: 
Patient Characteristics 
 Following the enrollment period lasting from November 2005 through May 
2007, 107 patients were screened for enrollment.  15 patients were rejected for 
multiple reasons.  These included:  prior surgery at the site of primary tumor 
(n=10), imaged off protocol (n=3), and withdrawal of consent (n=2).   This left a 
total of 92 patients.  Of these 22 were referred for surgical evaluation at the time 
of first follow-up.  Of those, 16 had no evidence of disease, responders, and 6 
were found to have residual disease, non-responders.  For the clinical follow-up 
arm, there were 6 patients with evidence of residual disease, non-responders, 
and 64 patients that responded to treatment.  Because this analysis also made 
use of the archived radiation treatment plan, various archiving errors further 
reduced the useable population of 92, n=14.    Additionally, patients with 
extreme anterior or posterior rotation of the head and neck were excluded for the 
analysis because of the difficulty in registering such patients, n = 10.  This left 49 
responding patients and 6 non-responding.   
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SUV and Treatment Response 
 SUV was first analyzed to determine if any associations with response to 
treatment existed.  Pre- and post-RT absolute SUV metrics were tested as well 
as relative change in SUV.   Summaries of all results are presented in table 3.1.   
 The SUVPeak contour was defined on pre-RT PET images as an 
approximately 1 cm3 volume.  This volume was then deformably mapped to the 
post-RT PET/CT study.  The calculated pre-RT SUVPeak of the most 
metabolically active volume of responding primary tumors was found to be 10 ± 
6.7.  In non-responding patients, the pre-RT SUVPeak was 13 ± 5.0.  No 
statistically significant differences were found between the SUV values in these 
two groups (P> 0.05).  The distribution of SUVPeak values are shown in figure 
3.2a.  However, statistically detectable differences were found between the post-
RT SUVPeak values of responding tumors (2.4 ± 0.7) and non-responding (4.6 ± 
1.3) patients (P<0.01).  The histogram distribution for this metric is shown in 
figure 3.2b.  The separation between SUVPeak values of responding and non-
responding patients is clearly visible.  Additionally, the relative change between 
the pre- and post-RT SUVPeak, expressed as fractional SUV was evaluated for 
this ROI.  No statistically discernable differences were found between fractional 
SUVPeak values for responding (0.3 ± 0.2) and non-responding (0.4 ± 0.1) 
patients (P>0.05).  The distributions of these values are illustrated in figure 3.2c.  
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Figure 3.2 Deformably 
aligned SUVPeak 
Historgram distributions of (a) 
pre- (b) post-RT , and (c) 
fractional SUVPeak derived 
from the 1 cm3 SUVPeak 
contour created on pre-RT 
PET images and deformed to 
post-RT PET images.
a) 
b) 
c) 
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The SUVMax metric was evaluated next.  SUVMax, a single pixel value, is 
hypothesized to represent the maximum tumor burden.  This value was 
determined from a user defined volume that fully circumscribed the FDG-avid 
regions.  The calculated pre-RT SUVMax was found to be 19 ± 7.7 in patients 
who responded to RT.  In non-responding patients, the pre-RT SUVMax was 18 ± 
5.9.  No statistically significant differences were found between the SUV values 
in these two groups (P> 0.05).  The distribution of pre-RT SUVMax values are 
shown in figure 3.3a.  However, statistically detectable differences were found 
between the post-RT SUVMax values of responding tumors (4.5 ± 1.3) and non-
responding (6.7 ± 2.0) patients (P<0.01).  The histogram distribution for this 
metric is shown in figure 3.3b.  The separation between SUVMax values of 
responding and non-responding patients is clearly visible, yet not as pronounced 
as seen for the SUVPeak contour.  The relative change between the pre- and 
post-RT SUVMax, was found to be statistically significant (P<0.05).  The 
distribution of fractional SUVPeak for responding (0.3 ± 0.2) and non-responding 
(0.4 ± 0.2) patients is shown in figure 3.3c.  
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Figure 3.3 SUVMax 
histograms 
Histogram distributions of (a) 
pre- (b) post-RT, and (c) 
fractional SUVMax derived 
from a user defined region 
that fully resolved the FDG 
avid region. 
c) 
b) 
a) 
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The 50% isocontour volume was defined on pre-RT PET images and 
encompassed all pixels in the FDG-avid volume that were within 50% of the 
maximum pixel value.  This volume was then mapped to the post-RT PET/CT 
study.  The calculated pre-RT SUV for the threshold PET-based contour was 
found to be 11 ± 5.1.  In non-responding patients, SUVMean for the 50% 
isocontour was 11 ± 5.9.  No statistically significant differences were found 
between the SUVMean values in these two groups (P> 0.05).  The distribution of 
SUVMean values for the threshold ROI are shown in figure 3.4a.  However, 
statistically detectable differences were found between the post-RT SUVMean 
values of responding tumors (2.8 ± 0.5) and non-responding (3.4 ± 0.7) patients 
(P<0.05).  The histogram distribution for this metric is shown in figure 3.4b.  
Finally, the relative change between the pre- and post-RT SUVMean for this 
ROI, expressed as fractional SUV was evaluated.  No statistically discernable 
differences were found between responding fractional SUVMean (0.3 ± 0.2) and 
non-responding (0.4 ± 0.2) fractional SUVMean at the 95% confidence level.  
The distributions of these values are illustrated in figure 3.4c. 
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Figure 3.4 Deformably 
aligned PET-based threshold 
contour 
Historgram distributions of (a) 
pre- (b) post-RT , and (c) 
fractional SUVMean derived from 
deformably mapped threshold 
contour that encompasses all 
pixels within 50% of SUVMax. 
 
 
 
a) 
b) 
c) 
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The final contour to be evaluated was the CT-based GTV.  The GTV 
contours created for this study were created on planning CT images and then 
mapped separately to pre- and post-RT PET/CT images, where they were 
utilized as ROIs to determine SUV.  The calculated pre-RT SUV for the gross 
tumor volume of patients who ultimately responded to treatment was 6.7 ± 3.3.  
In non-responding patients, the pre-RT SUV was 5.8 ± 2.1.  No statistically 
significant differences were found between the SUV values in these two groups 
(P> 0.05).  The distribution of SUVMean values derived for the total tumor 
volume is shown in figure 3.5a.  However, statistically detectable differences 
were found between the post-RT SUV values of responding tumors (2.6 ± 0.4) 
and non-responding (3.2 ± 0.7) patients (P<0.05).  The histogram distribution for 
this metric is shown in figure 3.5b.  The separation between SUVMean values of 
responding and non-responding patients is clearly visible, but marked overlap 
between the two groups is seen.  Additionally, the relative change between the 
pre- and post-RT SUV, expressed as fractional SUV was evaluated for this ROI.  
No statistically discernable differences were found between responding 
fractional SUVPeak (0.5 ± 0.3) and non-responding (0.6 ± 0.2) at the 95% 
confidence level.  The distributions of these values are illustrated in figure 3.5c. 
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Figure 3.5 Deformably 
aligned GTV contour 
Historgram distributions of (a) 
pre- (b) post-RT , and (c) 
fractional SUVMean derived 
from the GTV contour 
created on planning CT 
images and deformably 
mapped to pre- and post-RT 
PET/CT images. 
a) 
b) 
c) 
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  Responder Non-responder 
  Pre-RT Post-RT 
Fractional 
SUV Pre-RT 
Post-
RT 
Fractional 
SUV 
SUVMax 19 ± 7.7 4.5 ±1.3 0.3 ± 0.2 18 ± 5.9 6.7 ± 2.0 0.4 ± 0.2 
SUVPeak 10 ± 6.7 2.4 ± 0.7 0.3 ± 0.2 13 ± 5.0 4.6 ± 1.3 0.4 ± 0.1 
50% 
Isocontour 11 ± 5.1 2.8 ± 0.5 0.3 ± 0.2 11 ± 3.9 3.4 ± 0.7 0.4 ± 0.2 
GTV primary 6.7 ± 3.3 2.6 ± 0.4 0.5 ± 0.3 5.8 ± 2.1 3.2 ± 0.7 0.6 ± 0.2 
Background 4.9 ± 1.0 4.6 ± 1.0 0.9 ± 0.2 4.3 ± 1.1 4.0 ± 1.0 0.9 ± 0.3 
 
 
Table 3.1 Average SUV values derived from deformably mapped volumes 
for responding and non-responding patients. 
Tabulated here are absolute and fractional SUV metrics for the cohort stratified 
by primary tumor response.  One standard deviation is presented along with 
each mean value.  Statistically discernable differences between responding and 
non-responding patients are shown in bold face type (P<0.05). 
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Predicting RT Outcomes with SUV  
Absolute post-RT SUV was identified as the superior metric to 
differentiate patients responding to RT from those who did not.  Next, post-RT 
SUV decision thresholds were determined for each technique based upon 
tabulated data from each ROC curve.  In figure 3.6, the ROC curves for post-RT 
SUV from each technique are shown.  For reference, the curve representing 
performance of pure guessing is plotted as a dashed line.  Additionally, the 
sensitivity and (1 – Specificity) for the post-RT contrast enhanced CT is shown 
as a single data point for comparison.  The binary end point, response to RT, 
was defined as a reading of complete radiographic response.  All other 
radiographic endpoints:  partial response, stable disease, and progressive 
disease were defined as non-responders.  Post-RT contrast enhanced CT was 
found to have a sensitivity of 80% and a specificity of 92%.  Radiographic 
analysis yielded one false positive.  Overall, CT had a positive predicted value of 
50%.   
Decision thresholds that maximize sensitivity and minimize (1 – 
specificity) for each technique were selected from tabulated ROC curves.  For 
the SUVMax metric, a post-RT absolute SUV decision threshold value of 6.4 was 
selected.  Based upon this cutoff, sensitivity (80%) and specificity (94%) were 
calculated.  This cutoff point led to one false negative.  The positive predictive 
value of post-RT SUVMax was calculated to be 57%.  This result is slightly better 
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than what was found for contrast enhanced CT and notable for performing better 
than guessing.   
The best performing technique was the SUVPeak metric.  A post-RT SUV 
decision threshold of 3.5 was selected from the tabulated ROC analysis.  This 
cutoff point yielded the highest sensitivity of any method, 100%, and a very high 
specificity, 94%.  Notably, this was the only technique to have zero false 
positives.  The positive predictive value was 63% and the negative predictive 
value was 100%, the highest values for all techniques investigated.   
The 50% threshold and GTV contour both performed poorly.  For the 
PET-based threshold contour, a decision threshold of 3.3 was selected.  Utilizing 
this cutoff, the sensitivity was found to be no better than contrast enhanced CT, 
80%, and the specificity was found to be worse, 88%.  Similar to CT evaluation, 
this analysis resulted in one false negative.  While the negative predictive value 
was high, 98%, the positive predictive value was less than 50%.  Results for 
SUVMean derived from the mapped GTV contour were similar.  A decision 
threshold of 2.8 was identified.  This resulted in one false negative.  The 
sensitivity was identical to all other techniques, aside from SUVPeak, but 
ultimately proved to have the worst specificity, 69%.  Furthermore, the positive 
predictive value of this technique was the lowest at 21%.  Table 3.2 displays the 
results of all ROC analyses. 
The SUVPeak method resulted in the largest area under the ROC curve, 
0.98 (0.89 – 0.99, 95% C.I.).  Both SUVMax and SUVMean derived from the 50% 
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threshold contour had areas of 0.93 (0.82 – 0.98 95% C.I.).  Finally, SUVMean 
determined for the GTV volume had the smallest area, 0.8 (0.67 – 0.90 95% 
C.I.).  First, consider the SUVPeak metric that resulted in the highest positive and 
negative predictive values.  Statistically significant differences in the area under 
the ROC curve were found between the SUVPeak metric and SUVMean derived 
from the GTV contour (P<0.05).   No statistically significant differences were 
found between the area under the SUVPeak curve and the area under the curves 
of all other metrics (P> 0.05).  Pair-wise comparisons between all other metrics 
found no significant differences in the area under each curve (P>0.05).
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Figure 3.6 ROC curves for the deformably aligned volumes 
ROC curves for SUVMax and SUVMean derived from the GTV contoured on 
planning CT images and a PET-based 50% threshold contour and SUVPeak are 
shown.  The single data point represents the sensitivity and specificity of 
contrast-enhanced CT for the study. 
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Table 3.2 Accuracy of response prediction with deformably mapped 
volumes 
Cutoff values were selected from ROC curves to classify patients as normal or 
abnormal.  The raw numbers for each error type are tabulated along with 
calculated sensitivity, specificity, positive predictive values, and negative 
predictive values.  The superior metric is denoted in bold face type. 
  CT SUVMax SUVPeak 50% Isocontour GTV Primary 
Decision threshold   6.4 3.5 3.3 2.8 
True positives 4 4 5 4 4 
False negatives 1 1 0 1 1 
True negatives 45 46 46 43 34 
False positives 4 3 3 6 15 
Sensitivity 0.80 0.80 1.00 0.80 0.80 
Specificity 0.92 0.94 0.94 0.88 0.69 
Positive predictive value 0.50 0.57 0.63 0.40 0.21 
Negative predictive value 0.98 0.98 1.00 0.98 0.97 
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Correlating SUV Derived from Bony Alignment Contours to Treatment 
Response 
 While the first major arm of this aim investigated the ability of SUV 
derived from mapped contours to assess and predict response to RT, the 
second arm investigated the impact of improved registration on treatment 
response monitoring.  For the second major arm of this specific aim, SUV was 
derived from pre-treatment volumes aligned to the C2 vertebra on pre- and post-
RT PET/CT images.  Pre- and post-RT absolute SUV metrics, as well as relative 
change in SUV, derived from the rigidly aligned contours were analyzed for 
correlations to response to RT.   Summaries of all results are presented in table 
3.3.   
 Post-RT absolute SUVPeak derived from contours mapped to pre- and 
post-RT PET/CT studies was the best performing metric in the previous 
analysis.  The calculated pre-RT SUV of the most metabolically active volume of 
responding primary tumors was found to be 10 ± 6.7.  In non-responding 
patients, the pre-RT SUVPeak was 13 ± 5.0.  These values are identical to those 
from the previous section as this contour is defined on pre-RT PET/CT images.  
Therefore, no statistically significant differences were found between the SUV 
values in these two groups (P> 0.05) as discussed above.  Contrary to the 
previous SUVPeak results, statistically detectable differences were not found 
between the post-RT SUVPeak values of responding tumors (2.6 ± 0.6) and non-
responding (2.8 ± 0.8) patients (P>0.05).  The histogram distribution for this 
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metric is shown in figure 3.7b.  For comparison, the histogram distribution for the 
deformably mapped SUVPeak volume is shown in figure 3.7a.   It is clear from the 
distributions that bony alignment of the pre-RT SUVPeak volume was not 
sufficient to capture the FDG-avidity of the residual tumor. Additionally, the 
relative change between the pre- and post-RT SUVPeak, expressed as fractional 
SUV was evaluated for this ROI.  Once again no statistically discernable 
differences were found between responding fractional SUVPeak (0.4 ± 0.4) and 
non-responding (0.3 ± 0.1) (P>0.05).   
The PET-based threshold contour was analyzed next. The calculated pre-RT 
SUV for the threshold PET-based contour was found to be 11 ± 5.1.  In non-
responding patients, SUVMean for the 50% isocontour was 11 ± 3.9.  As 
mentioned above, these volumes are defined on the pre-RT PET/CT images and 
the results of the previous analysis will not alter in the present scenario.  In 
contrast to the analyses with deformed contours, statistically detectable 
differences were not found between the post-RT SUVMean values of responding 
tumors (2.0 ± 0.4) and non-responding (2.1 ± 0.3) patients (P>0.05).  The 
histogram distribution for this metric is shown in figure 3.8b.  In figure 3.8a, the 
distribution of SUVMean derived from the mapped threshold contour is shown for 
reference.  Of note is the shift toward lower SUV values for the rigidly aligned 
contours, indicating incomplete resolution of the FDG-avid volume.  Finally, the 
relative change between the pre- and post-RT SUVMean for this ROI, expressed 
as fractional SUV was evaluated.  No statistically discernable differences were 
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Figure 3.7 Bony and deformed SUVPeak distributions 
Histogram distributions for deformably (a) and rigidly (b) aligned PET-based 
SUVPeak contour. 
a) 
b) 
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found between responding fractional SUVMean, 02 ± 0.1, and non-responding, 0.2 
± 0.1, fractional SUVMean, P>0.05. 
The final contour to be evaluated was the bony aligned CT-based GTV.  
The calculated pre-RT SUV for the gross tumor volume of patients who 
ultimately responded to treatment was 3.5 ± 1.3.  In non-responding patients, the 
pre-RT SUV was 5.6 ± 2.5.  No statistically significant differences were found 
between the SUV values in these two groups (P> 0.05).  As seen for all rigidly 
aligned contours, no statistically detectable differences were found between the 
post-RT SUV values of responding tumors (1.9 ± 0.3) and non-responding (2.1 ± 
0.3) patients (P>0.05).  The histogram distribution for this metric is shown in 
figure 3.9b.  Additionally, the relative change between the pre- and post-RT 
SUV, expressed as fractional SUV was evaluated for this ROI.  No statistically 
discernable differences were found between responding fractional SUVPeak (0.6 
± 0.2) and non-responding (0.5 ± 0.3) (P>0.05).   
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Figure 3.8 Bony and deformed PET threshold contour 
Histogram distributions for deformably (a) and rigidly (b) aligned PET-based   
50% threshold contour. 
 
a) 
b) 
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Figure 3.9 Bony and deformed GTV 
Historgram distributions for deformably (a) and rigidly (b) aligned CT-based GTV 
contour. 
 
a) 
b) 
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Table 3.3 Average SUV values for responding and non-responding patients 
from rigidly aligned volumes. 
Tabulated here are absolute and fractional SUV metrics derived from rigidly 
aligned ROIs for the cohort stratified by primary tumor response.  One standard 
deviation is presented along with each mean value.  No statistically discernable 
differences were found between SUV values of responding and non-responding 
patients (P<0.05). 
 
 
 
  Responder Non-responder 
  Pre-
RT 
Post-
RT 
Fractional 
SUV 
Pre-
RT 
Post-
RT 
Fractional 
SUV 
SUVPeak 10 6.7 2.6 0.6 0.4 04. 13 5.0 2.8 0.8 0.3 0.1 
50% 
Isocontour 
11 5.1 2.0 0.4 0.2 0.1 11 3.9 2.1 0.3 0.2 0.1 
GTV 
primary 
3.5 1.3 1.9 0.3 0.6 0.2 5.6 2.5 2.1 0.3 0.5 0.3 
  60 
Predicting RT Outcomes with SUV Derived From Bony Aligned Volumes 
In contrast to the excellent ability of SUV derived from deformably 
mapped contours to distinguish responding from non-responding patients, the 
bony aligned pre-RT volumes overall performed poorly.  In the previous ROC 
analyses, only those metrics that could significantly differentiate responding from 
non-responding patients were utilized.  In the current analysis, no rigidly aligned 
metrics met this benchmark. In figure 3.10, the ROC curves for post-RT SUV 
from each technique are shown.  For reference, the curve representing 
performance of pure guessing is plotted as a dashed line.  Additionally, the 
sensitivity and (1 – Specificity) for the post-RT contrast enhanced CT is shown 
as a single data point for comparison.  The post-RT contrast enhanced CT was 
found to have a sensitivity of 80% and a specificity of 92%.   
Decision thresholds that maximize sensitivity and minimize (1 – 
specificity) for each technique were selected from tabulated ROC curves.  For 
the SUVPeak metric, a post-RT SUV decision threshold of 3.1 was selected from 
the tabulated ROC analysis.  This cutoff point yielded the highest sensitivity of, 
100%, and specificity, 94%, for the deformably mapped contours.  However, for 
the rigidly aligned volumes the sensitivity (60%) and specificity (78%) were 
lower.  The decision threshold resulted in 2 false negatives in comparison to 
zero for the deformed contours.  The positive predictive value was 21% and the 
negative predictive value was 95%.  These values were lower than for contrast 
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enhanced CT, but the positive predictive value was the best for the rigidly 
aligned PET metrics.  
The 50% threshold and GTV contour both performed poorly.  For the 
PET-based threshold contour, a decision threshold of 2.0 was selected.  Utilizing 
this cutoff, the sensitivity was found to be no better than the rigidly aligned 
SUVPeak, 60%, and the specificity was found to be worse, 61%.  One false 
negative was identified.  While the negative predictive value was high, 94%, the 
positive predictive value was the lowest found, 14%.  Results for SUVMean 
derived from the rigidly aligned GTV contour were similar.  A decision threshold 
of 1.9 was selected.  This resulted in one false negative.  The sensitivity was 
better than all other techniques and identical to contrast enhanced CT, 80%.  
The specificity was 63%.  Furthermore, the positive predictive value of this 
technique was the second lowest at 18%.  Table 3.4 displays the results of all 
ROC analyses.
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Figure 3.10 ROC curves for rigidly aligned volumes 
 
ROC curves for SUVMean derived from the rigidly aligned GTV, PET-based 
50% threshold contour, and SUVPeak are shown.  The single data point 
represents the sensitivity and specificity of contrast-enhanced CT for the study. 
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  CT SUVPeak 
50% 
Isocontour GTV Primary 
Cutoff value   3.1 2.0 1.97 
True positives 4 3 3 4 
False negatives 1 2 2 1 
True negatives 45 38 30 31 
False positives 4 11 19 18 
Sensitivity 0.80 0.60 0.60 0.80 
Specificity 0.92 0.78 0.61 0.63 
Positive predictive 
value 0.50 0.21 0.14 0.18 
Negative predictive 
value 0.98 0.95 0.94 0.97 
 
Table 3.4 Accuracy of response prediction with rigidly aligned volumes 
Cutoff values were selected from ROC curves to classify patients as normal or 
abnormal.  The raw numbers for each error type are tabulated along with 
calculated sensitivity, specificity, positive predictive values, and negative 
predictive values. 
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Comparing SUV Derived from Bony and Deformable Alignment 
 To compare the performance of each technique, the area under each 
curve of the ROC plot was compared pair-wise.  SUVMean derived from the GTV 
contour resulted in the largest area under the ROC curve, 0.73 (0.55 – 0.90, 
95% C.I.).  This is in contrast to what was found with the deformably mapped 
contours, where the GTV contour had the smallest area under the ROC curve. 
SUVMean derived from the 50% threshold contour had an area of 0.56 (0.34 – 
0.79 95% C.I.).  Finally, SUVPeak was found to have an area under the ROC 
curve equal to 0.62 (0.31 – 0.92 95% C.I.).  Comparison of the area under the 
ROC curves for each rigidly aligned contour found no statistically significant 
differences (P>0.05).   
However, when comparing the rigidly aligned contour to the deformably 
mapped contours the results are markedly different.  First, consider the SUVPeak 
metric.  The difference between the areas under each ROC curve was found to 
be 0.37 (0.04 – 0.71 95% C.I.).  Deformably mapping the SUVPeak volume 
defined on pre-RT PET/CT images to post-RT images was found to significantly 
increase the area under the ROC curve (P<0.05) when compared to bony 
alignment of this volume.   Next, consider the 50% threshold contour.  The 
difference in AUC was between the two alignment techniques was found to be 
0.37 (0.14 – 0.59 95% C.I.).  This increase in AUC is significant at the 95% 
confidence level.  Finally, consider the only contour created on CT images, the 
GTV.  The difference in AUC between the two alignment methods was 0.07 (-
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0.07 – 0.22 95% C.I.).  This increase in AUC was not significant (P>0.05).  On 
the whole, deformable mapping of pre-RT volumes to determine SUV increased 
the ability of PET/CT to predict response to RT for this data set.   
Discussion: 
 Many studies assessing and predicting response to RT with 18F-FDG 
PET/CT have reported positive outcomes for patients that showed reduced FDG 
uptake [89-93].  Quantification of residual disease and subclinical response 
offers the possibility to obtain a detailed picture of tumor viability and has been 
sought for some time [94].  Recent studies have confirmed the ability of 
quantitative PET/CT to distinguish residual disease, but with little benefit over 
conventional imaging [34].  Limited usefulness of the modality may be related to 
tumor sampling and recent position papers have suggested that response 
analyses should move away from the traditionally used single pixel values to 
region based assessment [95].  However, the presence of gross anatomical 
changes and multiple imaging studies will require accurate localization of FDG-
avid volumes. 
 The appropriate volume to derive SUV from is a complex question.  Total 
tumor volume was investigated and defined on CT and PET images.  One 
potential benefit of using a larger volume is that they tend to have less variability 
in SUV than smaller ones [96].  This concept was reinforced by the bony aligned 
GTV ROC curve.  The GTV contour had the largest AUC most likely due to the 
large volume of tissue contained within, making it less susceptible to incomplete 
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resolution of the most FDG-avid region.  The GTV contour created on the 
planning CT images was the only metric not able to differentiate the SUV of 
responding and non-responding patients when deformably mapped to pre- and 
post-RT images.  This may have resulted from the larger volume used to 
determine SUV (33 cm3 vs. 1 cm3) that included necrotic as well as residual 
cancer cells.    Additionally, because the GTV was defined on CT images, 
misalignment between the inherently aligned PET and CT images could result in 
calculating SUV for undesired tissue.  In one study, misalignment in head and 
neck PET/CT was found to be as much as 1o or 7 mm [97].   
The most widely used, and smallest relative volume, has been SUVMax.  
The maximum pixel value has been used to assess potential residual disease 
because it was thought to represent the maximum tumor burden, although it may 
just represent the most convenient metric.  This metric is also known to be 
greatly affected by image noise and may not be the ideal metric [96].  
Alternatively, SUVPeak has begun to gain favor [95].  One potential drawback of 
the SUVPeak method would be a non-centrally located maximum pixel.  In this 
case, the 1 cm3 could potentially include adjacent normal tissue.  This scenario 
could be quite troubling for tumors with maximal dimensions less than 1.2 cm.  
The average lesion size for the cohort as measured on pre-RT CT was 2.7 cm.  
Lesions less than 1.2 cm did not have SUVPeak determined in this study.  The 
average largest diameter measureable on post-RT CT was 2.9 cm.    
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For the current cohort, SUVPeak of non-responding patients was 
significantly higher than patients who responded to treatment (4.6 ± 1.3 vs. 2.4 ± 
0.7, P<0.01) when derived from the deformably mapped volume.  After a 
decision threshold was selected, SUVPeak was the only method to have zero 
false negatives.  Additionally, the PPV for residual disease was 63%.  For post-
RT contrast enhanced CT, PPV was only 50%.  Because SUVPeak is centered on 
the most metabolically active region of a tumor, viable residual cancer cells are 
likely to be circumscribed by this volume [98-100].  Assessing response to 
treatment based upon FDG-uptake in the total tumor volume may reduce the 
post-RT SUV and mask the metabolic activity in this more critically important 
tumor region. 
Although significant differences were found between absolute post-RT 
SUV values of responding and non-responding patients this separation may be 
artificial.  The SUV value can be affected by many factors including patient 
preparation, incorrect cross-calibration of scanner and dose calibrator, and 
variable injection to imaging times [101].  Assessing the SUV of background 
tissue can be a powerful discriminator in determining if differences between two 
patient groups are real.  The liver has been suggested as a stable background 
measurement point, but all patients in this cohort were head and neck cancer 
patients and PET/CT images did not include the liver [95].  Alternatively, non-
visual cortex brain tissue was shown in one study to function well as a 
background measurement point [102].   The brainstem was selected as a 
background measurement point because it is often contoured in head and neck 
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treatment planning.  Post-RT SUVMean for the brainstem in the responding group 
(4.7 ± 1.1) and non-responding group (3.9 ± 1.0) were not significantly different 
(P>0.05).  This strengthens the case for SUV differences between the two 
patient groups representing real effects.   
When comparing the deformably aligned volumes to the alternate 
alignment to a bony structure the advantage was clear.  The alternative method 
of alignment was based upon registration to the C2 vertebra.   For all volumes 
considered, SUV derived from bony aligned volumes was not significantly 
different between responding and non-responding patients (P>0.05).  
Additionally, the use of deformably mapped volumes was found to significantly 
increase the AUC for the SUVPeak volume and the threshold contour ROC 
curves, but not for the CT-based GTV.        
Conclusions: 
 In conclusion, deformable image registration was found to improve region 
based response analysis.  Specifically, for the most metabolically active tumor 
regions, mapping this volume across longitudinal studies significantly improved 
the predictive power of PET/CT over bony alignment (P<0.05).  A post-RT SUV 
decision threshold of 3.5 was selected for SUVPeak.  Utilizing this cutoff, the PPV 
for PET/CT was 63%, markedly higher than post-RT contrast enhanced CT 
(50%).  However, because the number of non-responding patients was small (n 
= 6), the results of the study need validation.  The results of this aim support the 
hypothesis that voxel-by-voxel mapping of primary tumor volumes to serial F-
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FDG PET/CT images would improve region based response analysis.  
Incorporating deformable image registration into quantitative treatment response 
monitoring studies to more accurately localize residual disease may greatly 
impact patient management and allow for more timely intervention. 
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Chapter 4 
 
Specific Aim 2a 
 
Evaluate the potential to determine normal organ-at-risk (OAR) toxicity in 
patients treated with intensity modulated radiotherapy (IMRT) for head and neck 
cancers with 18F-FDG PET/CT. 
. Working Hypothesis: Parotid gland SUV will function as an objective 
imaging biomarker of salivary toxicity correlating with stimulated salivary 
flow (P<0.05). 
Purpose 
 As described in Chapter 2, current methods used to assess salivary 
toxicity in patients treated for head and neck cancers with RT are limited and 
perform poorly.  For instance, for the cohort employed in specific aim 1 only 
30/107 screened patients had any measure of salivary toxicity collected as part 
of the routine standard of care.  When salivary toxicity measures were collected, 
they were limited to xerostomia questionnaires only collected after RT.  Without 
baseline measures, assessing the toxicity of a treatment is particularly 
challenging.   
 The potential of imaging biomarkers to measure the effects of cancer 
treatments have been well documented [92, 103, 104].  Arming clinicians with an 
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in vivo continuous variable that functions as a surrogate for clinical endpoints 
has powerful implications for patient management.  Yet, relatively little attention 
has been paid to investigating the ability of imaging biomarkers to quantify 
normal organ-at-risk (OAR) toxicity [105-107].  The near drought of work in this 
area has lead to the establishment of groups like the Image Response 
Assessment Team (IRAT) whose sole purpose is to further the use of 
quantitative imaging for treatment response to therapy in the clinic.  Additionally, 
recent changes in reimbursement guidelines for PET from the Centers of 
Medicare and Medicaid will only increase the number of number of initial staging 
and follow-up PET scans being performed [108].  
 Because of the expanding role of PET/CT in patient management the 
opportunity exists for uses tangential to initial staging or follow-up.  Specifically, 
for patients with head and neck cancer, incidental collection of parotid 18F-FDG 
uptake was investigated as a surrogate for salivary function.  Sialometric data 
collected on the same day as PET/CT imaging studies were correlated with SUV 
determined for the parotid glands in this study.  Utilization of imaging biomarkers 
in this manner may allow for patient specific refinement of radiation treatment 
plans to reduce normal OAR toxicity.   
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Methods and Materials 
Patient Cohort 
 To test the working hypothesis for specific aim 2, a separate cohort was 
employed in which patients had pre- and post-RT PET/CT imaging and 
measures of salivary function collected at the same time point.  Patients were 
selected from an ongoing IRB approved protocol (LAB07-0050) designed to 
establish a database of the effects of RT on salivary flow.  Inclusion criteria 
included patients with histological conformation of head and neck cancer set to 
receive definitive RT, concurrent chemotherapy, or RT after surgery who were at 
least 18 years of age.  Patients who had previous RT of the head and neck were 
excluded.  Sialometric as well as subjective measures of salivary toxicity were 
collected at five time points.  The first collection was prior to the start of 
treatment.  While only a snapshot of salivary gland function, this time point will 
serve as the baseline measurement for saliva production.  The second time 
point is following RT, approximately 6 weeks.  The third time point is at four to 
six months after the completion of RT.  The fourth collection date is at one year 
post-RT (± 2 months).  Finally, the last collection time point is two years after the 
completion of treatment (± 3 months). 
Sialometric Evaluation 
 Whole mouth stimulated and unstimulated saliva was collected at each 
time point.  For the unstimulated collection, patients were instructed to refrain 
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from eating, drinking, or dental hygiene for at least 30 minutes.  The goal was to 
minimize the impact of all oral stimuli.  The subject was instructed not to induce 
salivation.  Each collection period lasted five minutes; this was shown on a 
digital timer in view of the patient.  During collection patients were instructed not 
to swallow and let the saliva accumulate in the floor of the mouth.  Every sixty 
seconds the patient was instructed to expectorate the accumulated saliva into 
100 mL vials.  This procedure was repeated every minute for the five minute 
collection period.  Each empty vial was massed prior to saliva collection.  After 
the patient’s saliva was collected the vial and saliva were massed.  The 
difference between the two measurements is the mass of the saliva.   
In order to measure the stimulated whole mouth saliva, the patient was 
instructed to rest for five minutes after the collection of unstimulated whole 
mouth saliva.  To induce salivation, 20 mL of a citric acid solution was held in the 
patient’s mouth for one minute.  The same methodology described for the 
unstimulated salivary collection was employed to collect stimulated salivary 
mass.  
For each patient stimulated and unstimulated baseline salivary flow 
measurements were assessed for abnormality.  Unstimulated whole salivary 
flow rates less than 0.1 mL/min and stimulated whole salivary flow rates less 
than 0.5 mL/min have historically been labeled as abnormal [109]. The salivary 
flow thresholds for abnormal flow were converted to mass cutoffs for the 
collection period of five minutes utilized in this protocol.  For the unstimulated 
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sialometric data, whole mouth salivary mass less than 0.5 g was classified as 
abnormal.  For the stimulated salivary data, whole mouth salivary mass less 
than 2.5 g was defined as abnormal baseline salivary function.    
 
Subjective Evaluation 
 Patient self-reported xerostomia questionnaires were utilized for 
subjective evaluation of salivary toxicity [75].  The patient completed a set of 
eight questions on the degree of difficulty talking, chewing, and swallowing due 
to perceived dryness.  Each question received a score of 1 – 10, with greater 
numerical value corresponding to greater perceived complication.  Finally, a 
summary score was created by summing the results of each question to produce 
a value between 0 and 80.   
Xerostomia Grade 
 Salivary toxicity was assessed using the EORTC/RTOG late effects 
toxicity scoring subjective, objective, management, analytic (SOMA) scale.  The 
analytic scale was employed to classify patients into grade 0 – 4 xerostomia at 
the time of first follow-up (approximately 50 days post RT).  The analytic scale 
separates patients into grades by assessing the saliva produced as compared to 
baseline.  The percentages are presented in table 4.1.   
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Table 4.1 RTOG/EORTC late effects analytic scale 
 Salivary toxicity grades are defined by the relative change in saliva production. 
  Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
Salivary 
flow/quantity 
> 95% of pre-
treatment 
76% - 95% 
of pre-
treatment 
51% - 75% 
of pre-
treatment 
26% - 50% 
of pre-
treatment 
0% - 25% 
of pre-
treatment 
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Volume Delineation 
 In order to evaluate the potential of using SUV as an objective imaging 
biomarker of salivary function, physician created parotid contours created on 
planning CT images were utilized.  The general delineation guidelines for the 
human parotid glands follow specific anatomical landmarks [110].  The superior 
boundary extends to the external auditory canal and mastoid process, figure 
4.1a.  Inferiorly, the parotids were contoured to the submandibular space, figure 
4.1b.  In the anterior direction, masseter muscle forms the boundary.  This is 
shown in figure 4.1c.  The sternocleidomastoid muscle forms the posterior 
border.  Laterally, the parotids are bounded by subcutaneous fat.  Finally, the 
medial border is formed by the posterior belly of the digastric muscle.   
However, these are only guidelines.   For instance, in 20% of the cases, 
the parotid will extend anteriorly past the masseter muscle [111].  Other, non-
patient, variations will also exist in the parotid contours.  For example, the 
adaptive protocol cohort had contour created by multiple physicians (n = 7).   In 
a 2005 study of the inter-observer contouring variations for head and neck 
anatomy, it was found that when compared to a mixed volunteer cohort , 
experienced head and neck radiation oncology specialist were able to reduce 
volume coefficient of variation (defined as the quotient of the standard deviation 
and the mean volume) by 16% for the parotid glands.  The presence of dental 
artifacts only impacted the contour volume coefficient of variation by 6%.  The 
center-of-volume standard deviation was reduced to 1 mm [112].  These 
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variations were found to be acceptable.  It is understood that while both 
anatomical and observer variations exist in the parotid contours, this is not 
expected to fundamentally alter the conclusions of the technique.   
The parotid glands were originally contoured on planning CT images 
collected for patient simulation.  These physician created volumes were then 
deformably mapped to the pre- and post-RT PET/CT images using the 
enhanced demons algorithm and the same methodology described for specific 
aim 1.  In figure 4.2, an example patient’s pre-RT PET/CT with deformably 
aligned parotid contours is shown.  In figure 4.2b and 4.2d, FDG-avid parotid 
glands are shown before and after RT, respectively.  The PET image has the 
upper window level set to the maximum SUV value within the parotids with the 
lower window set at 42% of this value [113].   
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a) b) 
c) d) 
Figure 4.1 Parotid anatomical boundaries 
The anatomical structures that form the common boundaries for the parotid 
glands (orange) are depicted in each frame (white arrow).  The submandibular 
glands are shown in purple.  (a)  The external auditory canal forms the superior 
boundary of the parotid glands.  The inferior boundary is formed by the 
submandibular space (b).  In (c), the masseter muscle forms the anterior 
boundary with the sternocleidomastoid muscle forming the posterior border.  The 
platysma forms the lateral border (d) while the posterior belly of the digastric 
muscle forms the medial border.  
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a) b) 
c) d) 
a) b) 
c) d) 
   
Figure 4.2 
Pre-RT CT (a) and PET (b) co-registered images with deformably aligned 
parotid contours (purple).  The green contour denotes the skin surface.  The 
post-RT CT (c) and PET (d) are also shown. 
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Results: 
Patient Characteristics 
 Fourteen patients were available for the current analysis that had pre- 
and post-RT PET/CT as well as salivary evaluation performed.  The cohort was 
composed mostly of males, n = 12, and few females, n = 2.  The average age of 
the group was 57 years with a range of 49 – 75 years.  Normal variations in 
saliva production have been shown to be age and gender independent [114, 
115].   
Tumor staging was based upon the American Joint Committee on 
Cancer.  Nine patients had stage four, three patients had stage three, and one 
patient each had stage one or two disease.  All primary tumors were located in 
the oropharynx.  The prescription dose was 70 Gy, n = 12, and 66 Gy, n = 2.  
Patients were treated once daily with a fraction size of 2.0 Gy, n = 4, 2.12 Gy, n 
= 8, or 2.2 Gy, n = 2.  The mean dose delivered to the parotid glands was 28 ± 6 
Gy.  The ipsilateral parotid gland, defined as the most proximal of the paired 
glands to the primary tumor, received mean doses of 36 ± 12 Gy.  The 
contralateral parotid gland received considerably lower mean doses of 20 ± 2 
Gy.     
Baseline Saliva Output 
 Measurements of baseline salivary flow were used to establish patients 
with pre-existing abnormal salivary function.  For the fourteen accrued patients, 
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unstimulated saliva production for a five minute collection period had an average 
value of 1.92 ± 1.04 g with a range of 0.45 – 4.04 g.  The distribution of baseline 
unstimulated flow is illustrated in figure 4.3.  Utilizing the specified cutoff for 
abnormal salivary function, for unstimulated salivary flow, 0.5 g, one patient was 
identified as having abnormal baseline function.  The vertical reference line in 
figure 4.3 depicts this cutoff.   
For the baseline stimulated saliva production, an average mass of 5.51 ± 
2.4 g was found with a range of 1.51 – 9.46 ).  The histogram in figure 4.4 
graphically displays the distribution of baseline stimulated saliva production.  
The cutoff for abnormal baseline stimulated whole mouth salivary flow, 2.5 g, 
identified one additional patient.  Furthermore, because xerostomia is 
fundamentally a subjective disorder, baseline XQL questionnaire scores were 
utilized to identify patients who believed their function was abnormal.  Two 
patients were found with XQL summary scores above the 40 threshold.  These 
data are illustrated in figure 4.5.  The scale XQL scale (0 – 80) has been 
truncated in the figure. 
In summary, 4/14 patients were identified as having abnormal baseline 
salivary function through objective and subjective measures.  The average 
unstimulated saliva mass in the abnormal baseline function group was 1.67 ± 
0.89 g.  The range of salivary mass was 0.67 – 2.84 g.  The normal baseline 
function group had an average unstimulated saliva mass of 2.02 ± 1.12 g with a 
range of 0.45 – 4.04 g.  There was no significant difference found between the 
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two groups (P>0.05).  Even when the two patients classified as abnormal based 
upon baseline XQL summary scores were not considered, the unstimulated 
saliva mass was not significantly greater in the “normal” group.  For the 
simulated salivary flow, the abnormal baseline function group produced an 
average of 4.32 ± 2.97 g with a range of 1.51 – 7.80 g.  The normal baseline 
stimulated flow group produced an average saliva mass of 5.98 ± 2.19 g.  The 
range of saliva mass values was 3.12 – 9.46 g.  No significant difference was 
found between the stimulated saliva mass of normal and abnormal baseline 
salivary function patients (P>0.05).  However, if the patients classified as 
abnormal based upon XQL summary scores are not considered the stimulated 
saliva mass for the normal function group is significantly greater than the 
abnormal function group, 1.9 ± 0.5 vs. 6.1 ± 1.1 P<0.05.   
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Figure 4.3 Baseline salivary mass 
Unstimulated salivary mass collected prior to treatment.  The vertical line 
represents the cutoff for “abnormal” function. 
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Figure 4.4 Baseline salivary mass 
Stimulated salivary mass collected prior to treatment.  The vertical line 
represents the cutoff for “abnormal” function. 
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Figure 4.5 Patient perceived baseline salivary function 
XQL summary score distribution prior to treatment.  The vertical line represents 
the median of the scale.  Note XQL scale (0 – 80) is truncated for display 
purposes. 
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Correlating Baseline Salivary Function and SUV 
  Following the deformation of all physician contoured pre-RT parotid 
volumes to the pre-RT PET/CT images, SUV was determined for the parotid 
glands.  Parotid gland pre-RT SUV for the baseline abnormal patients was found 
to be (1.2 ± 0.2), n = 4.  For the normal baseline salivary function patients, 
parotid gland pre-RT SUV was found to be (1.6 ± 0.3), n = 10.  This difference in 
SUV between the normal and abnormal baseline salivary function patients was 
significant (P<0.05).  This was in contrast to the insignificant differences of the 
stimulated and unstimulated saliva mass between the two patient groups.  The 
distribution of pre-RT SUV is shown in figure 4.6.   
 Next, the correlation between produced saliva and pre-RT SUV was 
investigated.  In figure 4.7, the relationship between stimulated salvia mass and 
pre-RT SUV is shown.  Moderate positive correlation between the two metrics, 
Pearson correlation = 0.41, was not significant (P>0.05).  For the unstimulated 
saliva mass produced, stronger negative correlations were observed, Pearson 
correlation = -0.57, that were insignificant (P>0.05).  Finally, the relationship 
between the subjective XQL summary score and SUV were assessed.  This is 
shown in figure 4.8.  Spearman’s rho showed moderate negative correlation 
between the subjective metric and pre-RT SUV, ρ = -0.46, P>0.05.   
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Figure 4.6 Baseline parotid SUV distributions 
The histogram distribution of parotid SUV values for the “normal” (blue) and 
“abnormal” (green) baseline salivary function patients. 
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Figure 4.7 Stimulated saliva mass versus SUV 
The baseline stimulated saliva mass [g] is plotted as a function of baseline 
parotid SUV.  Pearson correlation = 0.41, P>0.05. 
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Figure 4.8 Baseline XQL score versus parotid SUV 
The pre-treatment XQL summary scores did not show a strong correlation to 
baseline parotid SUV. 
  90 
Post-RT Salivary Output  
 Measurements of post-RT saliva production were utilized to establish 
salivary toxicity.  The average time to first follow-up saliva measurement was 52 
days after the completion of RT (range 42 – 62 days).  Although fourteen 
patients were analyzed for baseline correlations of saliva mass and SUV, only 
eight were employed for the post-RT analysis.  The data set was restricted for 
several reasons.  First, two patients failed to have first follow-up saliva collected.  
Second, patients previously identified as having abnormal baseline salivary 
function were not included in the analysis, n = 4.  In this manner, potential 
confounding factors associated with the deviant salivary function were 
eliminated.   
The average unstimulated saliva mass produced after RT was 1.16 ± 
1.52 g with a range of 0.47 – 4.90 g.  The average unstimulated saliva mass 
produced was reduced by 49% compared to baseline masses.  The distribution 
of post-RT unstimulated saliva collected at the first follow-up is shown in figure 
4.9.  For the stimulated condition, produced saliva had an average mass of 2.26 
± 2.08 g.  The range of simulated mass was 1.00 – 7.20 g.  The stimulated 
saliva distribution is shown in figure 4.10.  The average stimulated saliva mass 
produced was reduced by 50% when compared to baseline.  The distribution of 
fractional stimulated saliva output is shown in figure 4.11.  Based upon the 
EORTC/RTOG Late Effects Analytic Scale, patients with grade 4 (n =2), grade 3  
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Figure 4.9 Histogram distribution of post-RT unstimulated salivary mass 
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Figure 4.10 Histogram distribution of post-RT stimulated salivary mass 
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Figure 4.11 Histogram distribution of fractional stimulated saliva mass 
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(n = 3), grade 2 (n = 0), grade 1 (n = 2) and grade 0 (n = 1) xerostomia were 
identified. 
Correlating Post-RT Salivary Output and SUV 
 After the pre-RT parotid volumes were deformably mapped to the post-RT 
PET/CT images, post-RT SUV was collected for the parotid glands and 
correlated with post-RT salivary output measures.  In figure 4.12, unstimulated 
salivary flow versus absolute post-RT SUV of the parotid glands is plotted.  
Apart from one easily identifiable patient, all unstimulated salivary output was 
less than 1 g for the five minute collection period.  Post-RT SUV for the cohort 
ranged from 1.0 – 1.5.  Contrast this with the pre-RT unstimulated salivary 
output where 2/3 of the patients with unstimulated flow less than 1 g where 
classified as having abnormal baseline flow.  Interestingly, the patient with the 
greatest post-RT unstimulated salivary mass (4.9 g) also had the greatest pre-
RT unstimulated mass (4.0 g).  Because the parotid glands do not produce the 
majority of the unstimulated salivary output, correlations between SUV and 
unstimulated saliva mass were not expected to be strong nor significant.  This 
expectation was confirmed (Spearman’s ρ = 0.45, P>0.05).   
 Next, the stimulated salivary output was investigated.  In figure 4.13, the 
stimulated saliva mass versus absolute post-RT parotid SUV is plotted.  As was 
observed for the unstimulated saliva, the stimulated saliva mass range (1.0 – 7.2 
g) occupied a small range of SUV values (1.0 – 1.5).  The stimulated salivary 
mass was expected to correlate much closer with parotid SUV.  However, as  
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Figure 4.12 Unstimulated saliva mass and SUV 
The absolute post-RT unstimulated saliva mass did not correlate strongly with 
post-RT parotid SUV.  Spearman’s ρ = 0.45, P>0.05 
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Figure 4.13 Stimulated saliva mass and SUV 
The absolute post-RT stimulated saliva mass did not correlate strongly with 
post-RT parotid SUV.  Spearman’s ρ = 0.31, P>0.05 
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was observed for baseline stimulated salivary mass and absolute pre-RT SUV, 
minimal correlation was observed (Spearman’s ρ = 0.31, P>0.05). 
Additionally, the correlation between subjective measures of post-RT 
salivary toxicity and SUV were assessed.  The relationship between the 
subjective metric and SUV is illustrated in figure 4.14.  As expected XQL 
summary score was negatively correlated with SUV, although the results were 
not significant (P>0.05).   
Finally, relative changes in stimulated salivary output and SUV were 
investigated.  For 7/8 patients in the cohort, stimulated saliva output at the time 
of follow-up imaging was reduced.  Fractional stimulated saliva output for this 
group was 0.41 ± 0.28.  Reduction of saliva output paralleled SUV reduction; the 
imaging biomarker value was 0.80 ± 0.14.  One patient’s biomarker value 
indicated increased SUV from baseline (1.11).  This patient had a corresponding 
increase in stimulated saliva output with a fractional stimulated saliva value of 
1.14.  These metrics demonstrated strong and significant positive correlation 
(Pearson correlation = 0.93, P<0.01).  The relation is illustrated in figure 4.15.  
Furthermore, fractional SUV was correlated with xerostomia grade based on the 
RTOG/EORTC late effects analytic scale.  Xerostomia grade was negatively 
correlated with fractional SUV (Spearman’s ρ = -0.964, P<0.01).  This relation is 
shown in figure 4.16.
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Figure 4.14 Post-RT XQL score and SUV 
The post-RT XQL summary score did not correlate strongly with post-RT parotid 
SUV.  Spearman’s ρ = -0.56, P>0.05 
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Figure 4.15 Fractional stimulated saliva mass and SUV 
Fractional SUV was found to be positively correlated   (Spearman’s ρ = 0.93, 
P<0.01) with fractional stimulated salivary mass. 
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Figure 4.16 Fractional SUV and xerostomia grade 
Fractional SUV was found to be negatively correlated   (Spearman’s ρ = -0.964, 
P<0.01) to xerostomia grade as defined by the RTOG/EORTC late effects 
analytic scale. 
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Discussion: 
 Correlations between fractional parotid SUV and stimulated salivary mass 
suggest that Parotid SUV can function as an objective imaging biomarker of 
salivary function.  Patients with parotid glands that had reduced SUV similarly 
had reduced stimulated salivary mass following RT.  Further, parotid glands that 
exhibited increased SUV after RT paralleled increased stimulated salivary mass.  
Additionally, parotid gland fractional SUV had a strong negative correlation to 
xerostomia grade (P<0.01).  These data indicate that parotid SUV measured at 
the time of first follow-up after RT (approximately 8 – 9 weeks) may be a good 
surrogate for salivary toxicity.   
As discussed in chapter 2, the parotid glands are composed of many 
spherical clusters of serous cells, known as the acini.  The acinar cells are 
responsible for the production of saliva in the parotid glands.   In studies of 
animal parotids, the glandular composition was altered greatly following 
irradiation.  In one study of the rat parotid, the acinar cells comprised roughly 
80% of the glandular volume prior to irradiation.  Following the delivery of 30 Gy, 
the relative volume occupied by the acini was reduced to 20%.  Reduction in the 
quantity of acinar cells, responsible for producing the watery secretions, 
corresponded to a 90% reduction in the saliva produced [71].  In humans, the 
loss of acinar cells at 10 – 12 weeks after the completion of RT has been shown 
to be the primary histopathological finding.  For the current cohort, first follow-up 
salivary measurements were made seven weeks post-RT.  While the salivary 
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mass measurement was earlier than the 10 – 12 week time frame cited above, a 
plausible explanation for the 59% reduction in stimulated salivary flow in 7/8 
patients may be the reduction in the number of acinar cells.  Furthermore, the 
acute phase of parotid damage characterized by the reduction in salivary flow 
and lack of alteration in glandular composition in the rat parotid was found to 
only last 0 – 10 days after irradiation.    
In vivo and in vitro studies have demonstrated that uptake of FDG in 
tumors is directly related to the number of viable cells [99, 100].  Specifically, the 
numbers of cells expressing the GLUT-1 transporter correlate best with FDG 
uptake.  GLUT-1 is a protein that facilitates transport of glucose across the 
cellular membrane.  Expression of this protein is ubiquitous in human tissue and 
is responsible for basal glucose uptake.  As the parotid glands are composed 
primarily of the serous acinar cells, which express GLUT-1, FDG uptake should 
be proportional to the number acinar cells.  By consequence, parotid FDG 
uptake may be proportional to saliva production.   
Although differences between parotid gland pre-RT SUV for patients 
deemed to have abnormal and normal baseline flow were statistically significant, 
this determination was arbitrary.  Consider the patient classified as abnormal 
based upon baseline stimulated salivary mass.  This patient produced a salivary 
mass of 2.2 g.  This was based upon the calculated mass cutoff for a five minute 
saliva collection period.  Based upon the low stimulated salivary mass, one 
might expect a correspondingly low parotid SUV.  It was found that this patient 
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had the second lowest pre-RT SUV (1.0).  On the other hand, the patient who 
produced the greatest baseline stimulated salivary mass (7.8 g) did not have the 
greatest baseline parotid SUV (1.6).  More telling were the weak correlations 
between SUV and stimulated salivary mass.  So while SUV may be related to 
the quantity of saliva produced, the lack of correlation between pre-RT SUV and 
stimulated salivary mass suggests that other cofounding factors are most likely 
present.  On possible factor is the imperfect correlation between SUV and FDG-
uptake.  Previous reports have shown correlation coefficients as low as 0.84 
[99].   
Other investigators have found absolute saliva mass is often not the 
variable that correlates closest with xerostomia [115].  Rather, it has been 
suggested than relative change in an individual’s saliva production is more 
important.  This logic seems reasonable in light of the wide range of baseline 
salivary masses that patients feel constitute normal salivary function (2.55 – 9.46 
g).  This was confirmed for the current cohort where the strongest correlations 
were found between relative changes in stimulated salivary flow and SUV 
(Pearson correlation = 0.93, P<0.01).  Finally, xerostomia grade was shown to 
be negatively correlated with fractional SUV (Spearman’s ρ = -0.964, P<0.01).  
This suggests that as patients have SUV values closer to baseline values, 
salivary toxicity should be reduced. 
This study is limited in several respects.  First, the imaging biomarker was 
validated against measurements of salivary flow, a metric that is known to have 
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large variability.  However, little else exists in the way of objective measures of 
salivary toxicity.  Second, the study was limited to a small number of patients.  
The protocol to establish a database of salivary toxicity from RT at The 
University of Texas MD Anderson Cancer Center is one of the first at this 
institution.  With an accrual goal of 500 patients, the potential to fully investigate 
the association between SUV and saliva production is great.  Finally, salivary 
output was measured as whole mouth salivary mass and not collected from 
individual glands.  As detailed earlier, saliva results from the contributions of 
three major glands in addition to multiple minor glands [60].  Although fractional 
SUV correlated well with whole mouth stimulated salivary flow, saliva produced 
from other glands was possibly contaminating this measurement.  However, this 
contamination was expected to be minimal.  This is because the submandibular 
and sublingual glands receive large enough doses that saliva production after 
RT is effectively non-existent [42].    
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Conclusions: 
 In conclusion, pilot data suggest that parotid gland SUV would be well 
suited as an imaging biomarker for salivary toxicity.  Relative change in parotid 
gland SUV correlated significantly with relative change in stimulated whole 
mouth salivary flow (P<0.01) and toxicity grade as defined by the RTOG/EORTC 
late effects analytic scale (P<0.01).  The ability to assess parotid function using 
incidentally collected parotid uptake of FDG has great potential to decrease the 
reliance on poor measures of salivary toxicity like saliva collection and rarely 
used modalities like salivary gland scintigraphy.  The results of specific aim 2a 
supported the hypothesis.        
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Chapter 5 
 
Specific Aim 2b  
 
To quantify and model the dose-metabolic response of the parotid glands in 
patients treated with IMRT for head and neck cancer using 18F-FDG PET/CT 
Working Hypothesis:  Predicted post-RT parotid SUV will correlate with 
whole mouth stimulated salivary flow (P<0.05). 
Purpose 
 In the preceding study, Specific Aim 2a, the goal was to evaluate the 
potential use of SUV as an objective imaging biomarker of parotid function.  In 
the small pilot cohort, it was observed that changes in SUV between baseline 
and follow-up correlated significantly with changes in stimulated salivary output.  
The application of novel imaging biomarkers holds great promise.  However, no 
matter how well the biomarker may describe the physiologic process in question 
it is ultimately limited to describing the current functional status.  In the case of 
Specific Aim 2a, the dose has been delivered and the parotid glands have been 
injured.  Simply quantifying the damage can do little to alleviate the salivary 
toxicity.   
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The purpose of Specific Aim 2b, was to predict parotid post-RT SUV prior 
to the delivery of treatment.  To accomplish this task, a phenomenological model 
of the dose-metabolic response relationship was created using only pre-RT 
metrics.  The ability to estimate patient specific toxicity holds great promise for 
evaluation and refinement of radiation treatment plans.      
Methods and Materials: 
Patient Cohort 
 In order to construct a population based model of dose-SUV response, 
the patient cohort from Specific Aim 1 was exploited.  As described earlier, these 
patients received pre- and post-RT PET/CT studies in order to assess and 
predict response to radiotherapy for head and neck cancers.  The protocol did 
not specify the collection of salivary flow measurements, subjective salivary 
assessment through xerostomia quality of life questionnaires, or physician 
assessment of salivary toxicity.  However, as elucidated earlier, the incidental 
collection of parotid FDG-uptake can have many tangential uses.  Following this 
rationale, parotid SUV from patients enrolled in this protocol were utilized to 
model the dose-SUV response.  Details of the cohort are provided in chapter 3. 
 To validate the dose-SUV response model, the patient cohort from 
Specific Aim 2a was employed.  Patients enrolled in this IRB approved protocol 
had objective and subjective assessments of salivary function collected, as well 
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as, PET/CT imaging studies.  Details of the validation cohort are provided in 
chapter 4. 
Phenomenological Dose-Metabolic Response Model 
 The relative change in parotid FDG-uptake, expressed as fractional SUV, 
at 8 – 9 weeks after the completion of RT was modeled phenomenologically 
using pre-RT metrics.  As shown previously, for the validation cohort, fractional 
SUV had strong and significant correlations to xerostomia grade and fractional 
stimulated saliva output.  Modeling the continuous variable, fractional SUV, may 
allow a richer and more thorough evaluation of salivary toxicity than previous 
NTCP techniques that rely upon binary endpoints [116]. 
 Two approaches were employed to model the dose-metabolic response.  
First, a mean dose-SUV model was assessed.  Second, a voxel-based dose-
SUV model was constructed.  In both scenarios, fractional SUV was modeled as 
a function of a single parameter incorporating both planned physical dose and 
pre-RT SUV. 
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Metabolic Dose 
 To assess and model the functional dependence of fractional SUV, we 
introduced a figure of merit called metabolic dose.  The metabolic dose was 
defined as,  
   
 
where physical dose is the clinically planned dose distribution.  The metabolic 
dose term weights the planned physical dose by the baseline SUV.  In this 
manner, voxels with greater planned dose or initial metabolic function are 
expected to have greater reductions in baseline SUV than those voxels with 
lower planned dose or lower initial metabolic function.  Assuming the parotid’s 
density is equal to water, the units are in cGy.   
The metabolic dose concept is illustrated in figure 5.1.  In figure 5.1a, the 
relation of the parotid glands and the planned dose distribution is shown.  From 
the image, it is clear that the most medial portions of the parotid glands will 
experience the highest doses.  The most medial portions of the parotid glands 
are also observed to be the most metabolically active as evident in figure 5.1b.  
Consequently, the numeric value of the metabolic dose in this region will be the 
highest.  As expected, the reduction of SUV in these regions was greatest as 
exemplified in figure 5.1d.   
[cGy] Dose Physical * [Kg/L] SUV RT-PreDMet =
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Figure 5.1 Metabolic Dose  
Approved dose distribution with the parotids illustrated in purple.  Skyblue 
denotes 45 Gy; green denotes 30 Gy; yellow denotes 26 Gy; and blue, 20 Gy.  
(b)  Snapshot of baseline parotid SUV. The upper scale represents absolute pre-
RT SUV.  (c)  Metabolic dose distribution for the parotid glands. (d)  Biomarker 
distribution for the parotid glands after RT.  In the upper scale, SUV is presented 
as a fraction of the baseline SUV. Of note is the correspondence between areas 
of highest DMet and lowest biomarker
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Volume Delineation  
 As mentioned above, the parotid metabolic response model was 
constructed using the patient cohort from specific aim 1.  The parotids for this 
cohort were contoured on planning CT images by the treating physician.  For the 
mean dose-SUV model, the parotid contours were mapped to pre- and post-RT 
PET/CT images using the contour mapping workflow specified in specific aim 1.   
 In the case of the voxel-based model, the parotid contours created on the 
planning CT images were once again exploited.  However, this model required 
one-to-one correspondence between pre- and post-RT SUV as well as dose at 
the voxel level.  To facilitate this, the enhanced demons algorithm was utilized, 
but rather than mapping contours the image sets were deformed.  Briefly, the 
deformable transformations that resulted from CT-to-CT alignment were applied 
to the corresponding PET images.  As a result, the pre- and post-RT PET 
images were aligned to the planning CT image.  The detailed methodology to 
perform this within the CAT workspace is discussed in the next section. 
Co-registration of Planned Dose and SUV 
 The following methodology details the steps required to align PET/CT 
images to a reference image set within the CAT image registration workspace.  
While not a fusion image viewer, the CAT workspace can be utilized to collect 
SUV (Body weight, lean body mass, or body surface area normalization) or 
uptake for a volume of interest.   
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 All serial PET/CT studies were identified in Stentor and uploaded to 
Evercore for retrieval as described earlier.    Prior to importing original patient 
treatment plans into the CAT workspace, it was necessary to contour the second 
cervical vertebrae for image alignment purposes.  Contouring was performed 
using Philip’s Pinnacle3 treatment planning software, version 7.6c.  After opening 
the CAT workspace, the original patient treatment plans were imported as 
detailed earlier.  
 The images were then preprocessed.  All serial PET/CT studies were first 
checked for concordance of slice spacing, thickness, and pixel size.  In the event 
that one of these imaging parameters did not match, the Image Guided 
Radiation Therapy (IGRT) Utilities software package created by our group was 
utilized to re-sample the images appropriately.  Next, the planning CT imaging 
parameters were inspected for concordance with the PET/CT parameters.  
Again, if the parameters differed, the image was re-sampled appropriately.  By 
matching the imaging parameters of each data set we can achieve voxel-by-
voxel correspondence for the planning CT and serial PET/CT studies.   
 The next steps resemble those described in chapter 3 for the contour 
deformation methodology.  First, the bony alignment algorithm discussed in 
chapter 3 was utilized to align the C2 vertebrae of the reference and daily image 
sets.  To deform the PET/CT study of interest, the advanced options were used 
from the deformation dialog box and batch registration was selected.  Most 
importantly, the direction of deformation was specified as Daily -> Reference.  
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The DICOM PET images corresponding to the current PETCT study were then 
selected.  The deformation field mapping the Daily CT to the Reference CT was 
applied to each voxel in the PET image, producing a PET image aligned to the 
planning CT.  
 Before dose, pre- and post-RT SUV can be extracted from each contour 
the dose from the approved treatment plan must be collected.  Using the 
IGRTDumpDose script in the Pinnacle treatment planning system extracted the 
required data.  Finally, using the advanced options menu, the “Dump PET & 
Dose” function was utilized to extract data for every voxel within the contours 
contained in the alignment set.  The data were output to a text file containing 
each voxel location along with dose, pre- and post-RT SUV. 
 
Validation of the Models 
 After a mathematical form of the dose-metabolic response relationship 
was selected, the model was validated using the patient cohort from specific aim 
2a.  Initial validation consisted of evaluation of the R2 statistic.  However, 
graphical techniques are often the most telling validation of a models 
performance.  For both the mean and voxel-based dose-SUV response models, 
plots of predicted versus observed fractional SUV were constructed.  For a 
perfectly performing model, data points on these plots should lie along the line y 
= x.  Therefore, a well performing model should have a strong linear correlation 
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between the predicted and observed values.  Spearman’s correlation was 
utilized to assess these correlations and statistically significant results were 
defined as having P < 0.05.  Relative errors were computed as, (Predicted – 
Observed)/Observed *100. 
Results: 
Fractional SUV and Metabolic Dose 
 For the mean model, the mean planned dose and pre-RT SUV of the 
parotid glands was used.  In figure 5.2, the fractional SUV is plotted as a 
function of these two variables.  The average dose delivered to the parotid 
glands for the population was 25.4 ± 6.0 Gy.  Mean dose to the parotid glands 
ranged from 14.4 – 42.8 Gy.  The clustering of the mean parotid doses is an 
artifact of the planning goal to keep the mean dose less than 26 Gy.  The 
fractional SUV observed for the population had an average value of 0.96 ± 0.24.  
The fractional SUV range stretched from a minimum value of (0.62) to a 
maximum of (1.85).  Overall, these data indicated that FDG-uptake was reduced 
following delivery of treatment.  However, a simple relationship between dose 
and fractional SUV did not seem to be present.    
 The relationship between fractional SUV and the metabolic dose figure of 
merit is shown in figure 5.3 for the population.  The overall shape of the curve 
suggests that fractional SUV has a consistent relationship to the figure of merit 
and matches well with the expected dependence.  As stated above, larger 
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metabolic dose values were expected to have correspondingly greater 
reductions in SUV.  This would translate into smaller fractional SUV values.  
Examining the extremes of the plot, a DMet value for one patient of interest was 
calculated to be (8667) with a fractional SUV of (0.73).  Whereas an example 
patient from the lower extreme with a DMet value of (2901) had a fractional SUV 
value of (0.90).  
 The raw data from figure 5.3 were binned for the purpose of modeling.  
Five bins were utilized to capture the overall shape of the curve.  The width of 
each DMet bin was 2600.  In figure 5.4, the mean value of each bin with one 
standard deviation is displayed.   
  116 
  
Figure 5.2 Fractional SUV dose response 
Fractional SUV is plotted as a function of whole organ planned mean dose. 
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Figure 5.3 Fractional SUV and DMet 
Fractional SUV is plotted as a function of the metabolic dose figure of merit.  
DMet is shown deconstructed in this plot. 
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Figure 5.4 Fractional SUV and DMet 
The average fractional SUV is plotted against the mean metabolic dose for each 
bin of width 2600.  The error bars represent one standard deviation. 
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Validation of the Mean Model 
For the mean dose-SUV model, the fractional SUV was modeled over a 
range of DMetabolic values extending from a minimum of 2235 to a maximum of 
7115.  A power law with a constant offset was selected to model the data over 
the range of values found in this population.  The functional form of this model is 
 
 
where a, b, and c represent the coefficients.   In the above equation, x 
represents the metabolic dose figure of merit.  The results of the non-linear least 
squares fit are shown in figure 5.5.  The constant a value was calculated to be 
3.6x105 with 95% confidence bounds of -2.8x106, 3.6x106. The constant b value 
was found to have a value of -1.7 with 95% confidence bounds of (-2.88, -0.52). 
Finally, the offset constant, c, had a value of 0.65 with 95% confidence bounds 
of (0.42, 0.87).  The adjusted R2 statistic for the fit was found to be 0.996.  The 
sum of squares due to error (SSE) was found to be 0.0004.   
 Next, the patient cohort from specific aim 2b was used to further validate 
the phenomenological model.  In figure 5.6, a scatter plot of the observed 
fractional SUV for this cohort versus the fractional SUV predicted from the mean 
cxaxf b += *)(
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dose-SUV model is shown.  The dotted line represents a perfectly performing 
model.  The mean relative error between the predicted and observed fractional 
SUV was 13%.  The maximum and minimum relative errors found were 76% and 
-13%, respectively.  The most accurately predicted fractional SUV had a relative 
error of 0.07%.  For the patient with the largest relative error the observed 
fractional SUV was (0.47), but the predicted value was (0.83).  However, this 
patient was classified as having “abnormal” baseline salivary function.  Finally, 
the predicted and observed values were found to have a strong and significant 
correlation, Spearman’s ρ=0.71, P<0.01.  The combination of fit statistics and 
graphical analysis indicate the phenomenological model performs well. 
Lastly, the correlation between the predicted fractional SUV and the 
observed fractional stimulated salivary output was assessed.  In figure 5.7, the 
fractional stimulated salivary mass is shown to be significantly correlated with 
predicted fractional SUV, Spearman’s rho = 0.79, P<0.05.  As observed in 
specific aim 2a, only one patient had SUV that increased beyond baseline and 
this corresponded to an increase in stimulated salivary mass.  However, the 
mean model predicts that two patients would have SUV increases from baseline.
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Figure 5.5 Fitting results for the mean model 
Mean metabolic dose and fraction SUV data are plotted with the resulting 
weighed fit for a constant offset power law. 
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Figure 5.6 Mean model validation 
The observed fractional SUV values are plotted against the fractional SUV 
values predicted from the mean model (Spearman’s ρ = 0.71, P<0.01).   
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Figure 5.7 Predicted SUV and observed saliva changes 
The observed fractional stimulated saliva mass was plotted as a function of the 
predicted fractional SUV (Spearman’s ρ = 0.79, P<0.05). 
 
 
 
  124 
Voxel-based Fractional SUV and Metabolic Dose 
The second technique used to construct the phenomenological model 
was voxel-based.  After co-registration of pre- and post-RT SUV with planned 
dose, the voxel data were binned.  The bin width was set at 2000, but expanded 
for the highest metabolic dose values to increase the number of voxels in the 
most starved bins.  In figure 5.8, the relationship between the metabolic dose 
figure of merit and fractional SUV as determined on a voxel-by-voxel basis may 
be examined.  The error bars represent one standard deviation.   
Once again a consistent relationship between the two variables was 
observed.  Furthermore, the shape of the distributions also conformed to the 
initial expectations of an inverse relationship between the fractional SUV and the 
metabolic dose figure of merit.  Of particular interest is the much wider range of 
metabolic dose values observed.  For the mean model, the metabolic dose 
metric range was up to 6.5x103, whereas the range for the voxel model was an 
order of magnitude larger, up to approximately 7.8x104.  As alluded to earlier, 
the narrow range of mean doses delivered to the parotid glands is the primary 
reason for the constricted range.  However, on a voxel-by-voxel basis the dose 
range was much larger, 67 Gy versus 28 Gy found for mean planned doses to 
the whole parotid glands.  Because of this, the voxel model is able to account for 
dose heterogeneities within the parotid glands. 
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 Figure 5.8 Voxel-based dose-SUV response 
The fractional SUV-metabolic dose relationship for the entire cohort was 
compiled for the entire cohort. 
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Validation of the Voxel Model  
The A log transform of the fractional SUV and metabolic dose was utilized 
to aide in the fitting.  A modified logistic function was utilized to model fractional 
SUV at the voxel level as a function of metabolic dose.  The functional form has 
been modified to prevent fractional SUV values of zero.  Additionally, a boundary 
condition was imposed on the voxel data.  At zero metabolic dose the fractional 
SUV is assumed to be one.  This means that if the patient were to receive no 
dose the SUV value should remain at baseline values.  The functional form of 
this model is 
 
 
 
 
where, a-e represent the coefficients.   In the above equation, x represents the 
metabolic dose figure of merit.  The results of the linear least squares fit are 
shown in figure 5.9.  The constant a value was calculated to be 0.4669 with 95% 
confidence bounds of (0.4434, 0.4905). The constant b value was found to have 
a value of 7.599 with 95% confidence bounds of (5.287, 9.912). The constant c 
that scales the metabolic dose value was found to have a value of 2.25 x 104 
with 95% confidence bounds of (2.1 x 104, 2.8 x 104).  The power value, 
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constant d, was found to have a value of 3.943 with 95% confidence bounds of 
(3.181, 4.706).  Finally, the offset constant, e, had a value of 0.5324 with 95% 
confidence bounds of (0.513, 0.5517).  The adjusted R2 statistic for the fit was 
found to be 0.9987.  The sum of squares due to error (SSE) was found to be 
0.0007.   
Next, the patient cohort from specific aim 2b was again used to validate 
phenomenological model.  In figure 5.10, a scatter plot of the observed fractional 
SUV for this cohort versus the fractional SUV predicted from the voxel-based 
dose-SUV model is shown.  The dotted line represents a perfectly performing 
model.  The mean relative error between the predicted and observed fractional 
SUV was 9.6%.  The maximum and minimum relative errors found were 65% 
and -22%, respectively.  The most accurately predicted fractional SUV had a 
relative error of approximately 0.2%.  The patient with “abnormal” baseline 
salivary function also plagued the voxel-based model.  For this patient the 
observed fractional SUV was (0.47), but the predicted value was (0.65).  The 
voxel-based model was able to improve the predicted fractional SUV for this 
patient, but still failed to fully describe the extent of SUV reduction.  There were 
two addition patients where fractional SUV was noticeably overestimated, 46% 
and 25%.  The fractional SUV was underestimated markedly for one patient.  
The observed fractional SUV in this case was (1.23), but the predicted value 
was only (0.96).  This represented a roughly 22% underestimation.  This patient 
also had “abnormal” baseline salivary function.  Finally, the predicted and 
observed values were found to have a strong and significant correlation, 
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Spearman’s ρ=0.94, P<0.01.  The combination of the adjusted R2 and graphical 
analysis indicate the voxel-based phenomenological model performed at least 
as well as the mean dose-SUV model and in many cases better.  Overall, the 
relative error was reduced from 13% to 9%.   
Lastly, the correlation between the predicted fractional SUV and the 
observed fractional stimulated salivary output was assessed.  In figure 5.11, the 
fractional stimulated salivary mass is shown to have a strong and significant 
correlation with our figure of merit, Spearman’s rho = 0.85, P<0.01.   
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 Figure 5.9 Fitting results for the voxel model 
 Mean metabolic dose and fraction SUV data are plotted with the resulting 
modified logistic model fit.  
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Figure 5.10 Voxel model validation 
The observed fractional SUV values are plotted against the fractional SUV 
values predicted from the mean model (Spearman’s ρ = 0.94, P<0.01).   
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Figure 5.11 Predicted SUV and observed saliva changes 
The observed fractional stimulated saliva mass was plotted as a function of the 
predicted fractional SUV (Spearman’s ρ = 0.85, P<0.01).   
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Discussion 
 Predicting normal tissue toxicity has long been a goal to improve patient 
outcomes [117].  Fully understanding the response of normal tissues is vitally 
important in determining tolerance doses.  Dose response modeling utilizing in 
vivo biomarkers offers the possibility for patient specific estimations of toxicity 
based upon biologic function.  Additionally, in comparison to other image-based 
dose-response studies, PET/CT offers a 3D technique that many clinicians have 
routine experience with [4, 45].  However, exploiting 18F-FDG PET/CT for dose-
response modeling is still in an embryonic stage [106, 107].     
 The first model developed as part of this thesis work was a mean parotid 
dose and SUV model.  Although the range of mean doses delivered to the 
parotid glands only spanned 28.4 Gy, mean dose to the parotid glands has been 
shown to be one the strongest predictors of salivary toxicity [39].  However, as 
shown in figure 5.2, a simple relationship between Dose and relative SUV 
change in the parotid glands was not evident.  We hypothesized that in addition 
to the mean dose delivered to the parotid glands, the baseline function of the 
glands should also be relevant.  A figure of merit called the metabolic dose was 
introduced to capture this interplay between the spatial dose distribution and 
glucose metabolism.  Because SUV is known to be proportional to the number of 
viable cells, dose delivered to more metabolically active regions were weighed 
more heavily with this metric and expected to experience greater reductions in 
SUV after treatment.  Although the selection of the metabolic dose metric was 
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serendipitous, motivation for its selection can be found through multivariate 
fractional polynomial regression analysis [118, 119].  This type of regression 
analysis is useful when the covariates in the model may be non-linear.  Utilizing 
the statistical package R, the influence of dose, pre-RT SUV, and the metabolic 
dose metric on regression models of fractional SUV was assessed using the 
voxel-based data.  While none of the three covariates listed were eliminated 
from the final model, the coefficients were illuminating as to the best metric for 
SUV response modeling.  For dose, the coefficient was -6.7 x 10-8 and the 
coefficient for pre-RT SUV was 8.5 x 10-2.  However, when the product of dose 
and pre-RT SUV, metabolic dose, was considered the coefficient was -2.5.  The 
coefficient for the metabolic dose metric was at least two orders of magnitude 
larger than the separated covariates.  This indicates that metabolic dose is the 
dominate covariate and supports the use of this figure of merit for modeling the 
SUV response relationship.  A plot of metabolic dose and parotid SUV relative 
change displayed a consistent relationship that conformed to expectations.  The 
mean model was fit with a constant offset power law.  The fit statistics indicated 
a good fit, but because the metabolic dose metric and fractional SUV are 
correlated this was expected. 
One of the potential drawbacks of the phenomenological model is that it 
was only applicable over the range of observed data.  Beyond these limits the 
model is ill behaved.  For instance, as the metabolic dose increases, the 
fractional SUV will asymptotically approaches the constant offset, which for this 
cohort was 0.65.  However, suggesting that parotid SUV relative change has a 
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minimum of 65% of baseline may be unrealistic.   Interesting and perhaps 
unsurprisingly, given the fractional SUV dependence observed, only three 
parotid glands broached this barrier in the model cohort.  For the test cohort, two 
patients were below the minimum value of 65%, one of which had abnormal 
baseline salivary function.  At the other extreme, as metabolic dose values 
approach zero the relative change goes to infinity.  This seems to be 
physiologically unlikely.  Increases in glucose metabolism are possible and were 
observed, but setting a ceiling value for increase is unclear.  In one study by 
Schwartz-Arad et al., the effects of compensatory hyperplasia following partial 
submanibulectomy in rats found increased salivary function and an 
approximately 154% increase in the number of acinar cells the remaining 
submandibular gland [120].   
 Graphical validation of the mean model was favorable.  Scatter plots of 
the predicted and observed fractional SUV for the mean model demonstrated 
highly positive correlation (ρ = 0.71, P<0.01).  Furthermore, because the ultimate 
goal is to predict the fractional SUV that would result from treatment prior to its 
actual delivery, observed changes in stimulated salivary mass were plotted 
against predicted changes in SUV.  Although highly correlated (Spearman’s ρ = 
0.79, P<0.05), when compared to figure 4.15 in chapter 4, it is apparent that the 
relation between fractional SUV, which serves as the imaging biomarker, and 
relative change in stimulated salivary mass was altered.  Specifically, when 
fractional SUV was evaluated as a biomarker only one individual had an 
increase in SUV and this corresponded to an increase in stimulated salivary 
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mass.  For the predicted values, two patients were predicted to have increases 
in SUV and it would be expected that both might have increased salivary output.  
However, this was not true for one of these patients and the actual stimulated 
salivary mass decreased by almost 20%.  Overall the mean dose-SUV response 
model represented an easily implementable method that, with further validation, 
may allow for individualized assessment of the salivary toxicity resulting from a 
treatment plan design. 
The second method used to construct the dose-SUV response model was 
based upon voxel-by-voxel correspondence of dose and SUV.  The benefit of 
this model is the ability to account for subtle differences in the spatial distribution 
of planned dose.  Figure 5.12 illustrates this with two similar dose volume 
histograms that led to very different functional outcomes.  The range of doses 
available at the voxel level was much larger than those available when whole 
organ mean dose was used (67 Gy vs. 28 Gy).  Because of this, a richer picture 
of the metabolic response was possible.  This was reflected in the reduced 
relative error for the voxel-based model (9% vs. 13%).  An examination of the 
observed vs. predicted fractional SUV plot showed that the model performed 
quite well (Spearman’s ρ = 0.94, P<0.01).   
The voxel-based relationship between the metabolic dose figure and 
fractional SUV suggested a sigmoidal dependence.  The general trend of this 
data matches with that found in scintigraphic studies of parotid gland excretion 
as measured by reductions in tracer uptake.  The voxel-based model differed 
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from the mean model in that whole organ function was reconstructed from sub-
glandular response.  By predicating sub-glandular response, the voxel-model 
was able to account for variations in the spatial distribution of dose.  However, 
this also meant that the voxel-based model was more susceptible to the 
accuracy of the dose calculation engine.  One recent study compared the 
Pinnacle3 version 7.6c superposition/convolution algorithm with Monte Carlo 
(EGS4) calculations for head and neck IMRT patients.  Mean doses to the 
ipsilateral and contralateral parotid only differed by -0.5% and -0.04%, 
respectively [121].  For the mean dose model, errors in the calculated dose were 
minor.  However, calculated doses from the surface down to 2 mm depth were 
shown to have relative errors that exceeded 5%.  The most superficial border of 
parotid glands was found at approximately 2 mm depth.  Even with these 
potential differences between the delivered and calculated dose, whole organ 
fractional SUV constructed from sub-glandular response agreed well with 
observed values of SUV.   
Additionally, the ability of the voxel-based model to account for potential 
hyperplasia may be limited.  As seen in figure 5.8, the voxel data failed to show 
evidence of SUV increases from baseline for low metabolic dose values.  
However, parotid mean SUV was observed to increase from baseline.  If the 
voxel-based model is utilized to reconstruct parotid mean SUV it will fail to 
account for observed increases.   
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 Figure 5.12 Parotid DVH comparisons 
For a high (square) and low (triangle) oral complication patient, the cumulative 
DVH displays surprisingly subtle differences.  Both patients had a whole organ 
planned mean dose less than 26 Gy. 
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 Consider a patient that had an observed increase in SUV of 23%.  The 
mean model predicted an increase of 10% while whole organ SUV reconstructed 
from the voxel-based model predicted an SUV decrease of 4%.   For the mean 
dose and SUV data, increases in SUV from baseline were observed.   
Conclusions 
In conclusion, the dose-SUV response relationship in the human parotid 
glands was quantified and modeled.  Utilizing only baseline metabolic function 
and the planned dose distribution, predicting parotid SUV change or salivary 
toxicity, based upon specific aim 2, became possible.  Two techniques were 
used to create the phenomenological models:  1) based upon whole organ 
planned mean dose and pre-RT SUV and 2) based upon dose and SUV at the 
voxel level.  Mean and voxel-based models performed well at predicting SUV 
changes in a validation cohort with relative errors of 13% and 9%, respectively.  
Predicted SUV changes and observed stimulated saliva mass changes 
correlated strongly for both models although some shifting of the relationship 
observed in specific aim 2a was observed.  The results of this aim supported the 
hypothesis. 
  139 
Chapter 6 
 
Summary and Conclusions 
  
Central Hypothesis: 
We hypothesize that more accurate image registration will lead to 
improved quantitation of tissue response to radiotherapy with 18F-FDG PET/CT 
imaging.  
Conclusions 
The central hypothesis of this work was an overarching statement that 
connected the myriad applications of 18F-FDG PET/CT investigated in this work.  
As described in the pages above, quantitative treatment response monitoring 
with 18F-FDG PET/CT holds great promise.   Colloquially, treatment response 
monitoring has referred to analysis of only neoplastic tissue.  However, such a 
narrow application of a paradigm changing technology will limit novel ways to 
improve patient management.  As such, this work was designed to improve upon 
the existing uses of this modality and expand its use to new and interesting 
vistas. 
In the first specific aim, the purpose was to apply deformable image 
registration techniques to a study designed to assess and predict response to 
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RT using PET/CT.  Total tumor volumes, defined on CT and PET images, and 
the most metabolically active volumes were investigated to find the most 
accurate method to judge response.  Secondly, two methods of aligning these 
volumes to serial PET/CT studies were tested.  The first relied upon a 
deformable image registration algorithm, while the second employed a more 
conventional bony alignment technique.  The deformably mapped SUVPeak 
volume was the best metric for predicting response to RT.  The PPV (63%) of 
this metric was greater than post-RT contrast enhanced CT (50%) and all other 
PET metrics (40%, 21%, and 57%).  When compared to bony alignment of the 
SUVPeak volume, deformable image registration led to significantly improved 
prediction of response to RT.  Specific aim 1 supported the working hypothesis 
that voxel-by-voxel mapping of primary volumes to serial F-FDG PET/CT images 
would improve region based tumor response analysis. 
In the second specific aim, the goal was to evaluate the use of a novel 
imaging biomarker for salivary function following RT.  To our knowledge, this 
was the first time the relationship between salivary output and salivary gland 
uptake of 18F-FDG has been investigated.  Relative change in parotid gland SUV 
was found to have strong and significant correlations to relative change in 
stimulated salivary mass (Pearson correlation = 0.93, P<0.01).  Utilizing the 
RTOG/EORTC Late Effects analytic scale, patients were stratified into 
xerostomia grade.  Although limited by patient number, individuals with parotid 
SUV closer to baseline values were found to have lower grade xerostomia at the 
time of first follow-up (Spearman’s ρ = -0.96, P<0.01).  Mapping pre-RT parotid 
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volumes across serial imaging studies yielded a novel method to assess salivary 
toxicity due to RT.  Specific aim 2a supported the hypothesis that parotid gland 
SUV would function as an objective imaging biomarker of salivary toxicity, 
correlating with stimulated salivary flow (P<0.05).  
 In the third specific aim, the goal was to construct a model of the dose-
SUV response relationship in the parotid glands to allow for pre-treatment 
prediction of post-treatment parotid SUV values.  Utilizing a figure of merit that 
captured both the planned dose and pre-RT SUV of the parotid glands, a 
phenomenological model of the relative change in SUV due to RT was 
formulated.  Two models were built, one based upon planned mean dose to the 
parotids and mean SUV and a second model based upon dose and SUV at the 
voxel level in the parotid glands.  Predicted and observed relative change in 
SUV correlated well for both the mean (Spearman’s ρ = 0.71, P<0.01) and 
voxel-based (Spearman’s ρ = 0.94, P<0.01) models.  Subsequently, the 
predicted relative change in parotid SUV, which was shown to function well as 
an imaging biomarker for salivary toxicity in specific aim 2a, was shown to 
correlate closely with the observed relative change in stimulated salivary mass 
at the time of first follow-up.  Co-registration of pre- and post-RT PET/CT images 
with planned dose distributions, achieved through the use of deformable image 
registration tools, made possible this novel dose-SUV response model. To our 
knowledge, this is the first time the feasibility of such a model for the human 
parotid glands has been demonstrated.  Specific aim 2b supported the 
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hypothesis that predicted parotid post-RT SUV would correlate with whole mouth 
stimulated salivary flow (P<0.05). 
 The central hypothesis of this work was that more accurate image 
registration would lead to improved quantitation of tissue response to RT with 
18F-FDG PET/CT.  In each aim deformable image registration facilitated 
improved quantitation for tumor as well as normal tissue.  The future of 
radiotherapy will most certainly see increased use of 18F-FDG PET/CT imaging 
for quantitative treatment response monitoring.  The application of deformable 
image registration to quantitative treatment response monitoring with 18F-FDG 
PET/CT could have a profound impact on patient management.  Accurate and 
early identification of residual disease may allow for more timely intervention, 
while the ability to quantify and predict toxicity of normal OAR might permit for 
individualized refinement of radiation treatment plan designs. 
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Appendix 
 
Addhdrinfo 
 The following code will add user specified content to DICOM PET image 
headers, copy all unaltered content, and create a new set of images containing 
user generated content. 
function Addhdrinfo 
  
%The following script will add a DICOM tag or alter a current tag in a 
%group of images 
  
%CAUTION!!  Unitl updated for user input of tag or tag value, MUST 
alter 
%code! 
  
PathName = uigetdir; 
d = datestr(now,30); 
mkdir(PathName,['Altered Images',d]); 
  
%get the file list in the given directory 
structFilesList = dir(PathName); 
structFilesList(1:2) = [];    %delete the default system directory name 
  
%Convert struct FilesList to char array 
cellFilesList=struct2cell(structFilesList); 
cellFilesName=cellFilesList(1,:); 
  
%Delete folder name 
TempDirFlag=cellFilesList(4,:); 
TempDirFlag=cell2mat(TempDirFlag); 
  
TempDirOrder=find(TempDirFlag); 
  
if ~isempty(TempDirOrder) 
    cellFilesName(TempDirOrder)=[]; 
end 
  
charFilesName=char(cellFilesName'); 
FileName=cellstr(charFilesName); 
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%Set the duration of the for loop by the number of patients in the 
selected 
%directory 
ptcnt=size(FileName, 1); 
  
%Read file and alter DICOM tags 
for i=1:ptcnt 
  
    %Filter to skip files without the .dcm file extension 
    TempFile=FileName{i}; 
  
    %Checks the files for the .dcm extension, if not .dcm exits loop 
and 
    %moves to the next file in the list 
    if length(TempFile)> 4 
        if ~isequal(TempFile(end-3:end), '.dcm') 
            continue; 
        end 
    else 
        continue; 
    end 
  
    %Writest the dicom header to a cell array 
    X =[PathName, '\', FileName{i}];     
    img=dicomread(X); 
    metadata = dicominfo (X, 'dictionary','DicomDict_Plan.txt'); 
  
    %DICOM tag to be added or altered 
    metadata.PatientSize = 1.65; 
  
    %Creates a new DICOM image with altered an altered DICOM tag 
    dicomwrite(img,[PathName,'\','Altered 
Images',d,'\',FileName{i}],... 
        metadata,'CreateMode','copy'); 
     
end 
Scanorder 
 The following script will open a series of images and place them in folders 
based upon chronology e.g. CT01, CT02 etc. 
%This script will rename image directories either to CT01 or CT02 and 
PET01 
%or PET02 
PathName = uigetdir; 
%Get the file list in the given directory 
FolderStruct = dir(PathName); 
%Delete the default system directory name 
FolderStruct(1:2) = []; 
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%Create structure of subdirectories 
  
for i=1:size(FolderStruct,1) 
    tempsubdir = dir([PathName,'\',FolderStruct(i,1).name]); 
    tempsubdir(1:2) = []; 
    if size(tempsubdir,1)> 1 
        disp([FolderStruct(i,1).name, ' has more than one series']); 
        continue; 
    end     
    structFilesList = dir([PathName,'\',FolderStruct(i,1).name,'\',... 
        tempsubdir.name]);     
    %delete the default system directory name 
    structFilesList(1:2) = []; 
    %Convert struct FilesList to char array 
    cellFilesList=struct2cell(structFilesList); 
    cellFilesName=cellFilesList(1,:); 
    %Delete folder name 
    TempDirFlag=cellFilesList(4,:); 
    TempDirFlag=cell2mat(TempDirFlag); 
    TempDirOrder=find(TempDirFlag); 
    if ~isempty(TempDirOrder) 
        cellFilesName(TempDirOrder)=[]; 
    end 
    charFilesName=char(cellFilesName'); 
    FileName=cellstr(charFilesName);     
    img =[PathName,'\',FolderStruct(i,1).name,'\',... 
        tempsubdir.name, '\', FileName{1}]; 
    info = dicominfo(img, 'dictionary','DicomDict_Plan.txt'); 
    FolderStruct(i,1).creationdate = info.InstanceCreationDate; 
end 
  
if (FolderStruct(1,1).name(1:2) == 'CT' & FolderStruct(2,1).name(1:2) 
== 'CT') 
    if (datenum(FolderStruct(1,1).creationdate,'yyyymmdd') < ... 
            datenum(FolderStruct(2,1).creationdate,'yyyymmdd')); 
        
movefile([PathName,'\',FolderStruct(1,1).name],[PathName,'\CT01']); 
        
movefile([PathName,'\',FolderStruct(2,1).name],[PathName,'\CT02']); 
        if (datenum(FolderStruct(3,1).creationdate,'yyyymmdd') < ... 
                datenum(FolderStruct(4,1).creationdate,'yyyymmdd')); 
            
movefile([PathName,'\',FolderStruct(3,1).name],[PathName,'\PET01']); 
            
movefile([PathName,'\',FolderStruct(4,1).name],[PathName,'\PET02']); 
        else 
            
movefile([PathName,'\',FolderStruct(3,1).name],[PathName,'\PET02']); 
            
movefile([PathName,'\',FolderStruct(4,1).name],[PathName,'\PET01']); 
        end 
    elseif (datenum(FolderStruct(1,1).creationdate,'yyyymmdd') == ... 
            datenum(FolderStruct(2,1).creationdate,'yyyymmdd')); 
        disp('Pre- and post-RT scans have same date.'); 
        continue; 
    else 
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movefile([PathName,'\',FolderStruct(1,1).name],[PathName,'\CT02']); 
        
movefile([PathName,'\',FolderStruct(2,1).name],[PathName,'\CT01']); 
        if (datenum(FolderStruct(3,1).creationdate,'yyyymmdd') < ... 
                datenum(FolderStruct(4,1).creationdate,'yyyymmdd')); 
            
movefile([PathName,'\',FolderStruct(3,1).name],[PathName,'\PET01']); 
            
movefile([PathName,'\',FolderStruct(4,1).name],[PathName,'\PET02']); 
        else 
            
movefile([PathName,'\',FolderStruct(3,1).name],[PathName,'\PET02']); 
            
movefile([PathName,'\',FolderStruct(4,1).name],[PathName,'\PET01']); 
        end 
    end 
elseif (FolderStruct(1,1).name(1:2) == 'PE' & 
FolderStruct(2,1).name(1:2) == 'PE') 
    if (datenum(FolderStruct(1,1).creationdate,'yyyymmdd') < ... 
            datenum(FolderStruct(2,1).creationdate,'yyyymmdd')); 
        
movefile([PathName,'\',FolderStruct(1,1).name],[PathName,'\PET01']); 
        
movefile([PathName,'\',FolderStruct(2,1).name],[PathName,'\PET02']); 
        if (datenum(FolderStruct(3,1).creationdate,'yyyymmdd') < ... 
                datenum(FolderStruct(4,1).creationdate,'yyyymmdd')); 
            
movefile([PathName,'\',FolderStruct(3,1).name],[PathName,'\CT01']); 
            
movefile([PathName,'\',FolderStruct(4,1).name],[PathName,'\CT02']); 
        else 
            
movefile([PathName,'\',FolderStruct(3,1).name],[PathName,'\CT02']); 
            
movefile([PathName,'\',FolderStruct(4,1).name],[PathName,'\CT01']); 
        end 
    elseif (datenum(FolderStruct(1,1).creationdate,'yyyymmdd') == ... 
            datenum(FolderStruct(2,1).creationdate,'yyyymmdd')); 
        disp('Pre- and post-RT scans have same date.'); 
        continue; 
    else 
        
movefile([PathName,'\',FolderStruct(1,1).name],[PathName,'\PET02']); 
        
movefile([PathName,'\',FolderStruct(2,1).name],[PathName,'\PET01']); 
        if (datenum(FolderStruct(3,1).creationdate,'yyyymmdd') < ... 
                datenum(FolderStruct(4,1).creationdate,'yyyymmdd')); 
            
movefile([PathName,'\',FolderStruct(3,1).name],[PathName,'\CT01']); 
            
movefile([PathName,'\',FolderStruct(4,1).name],[PathName,'\CT02']); 
        else 
            
movefile([PathName,'\',FolderStruct(3,1).name],[PathName,'\CT02']); 
            
movefile([PathName,'\',FolderStruct(4,1).name],[PathName,'\CT01']); 
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        end 
    end 
else 
    disp('Not all PET/CT series present'); 
end 
clear; 
 
 
Pthdrinfo 
 The following script will extract user specified content from a series of 
DICOM image headers and place all desired data into an excel file. 
function Pthdrinfo 
  
%Extract info from DICOM headers 
%Specifically for PET images 
%See line 74 for list of tags captured 
  
PathName = uigetdir; 
  
%get the file list in the given directory 
structFilesList = dir(PathName); 
structFilesList(1:2) = [];    %delete the default system directory name 
  
%Convert struct FilesList to char array 
cellFilesList=struct2cell(structFilesList); 
cellFilesName=cellFilesList(1,:); 
  
%Delete folder name 
TempDirFlag=cellFilesList(4,:); 
TempDirFlag=cell2mat(TempDirFlag); 
  
TempDirOrder=find(TempDirFlag); 
  
if ~isempty(TempDirOrder) 
    cellFilesName(TempDirOrder)=[]; 
end 
  
charFilesName=char(cellFilesName'); 
FileName=cellstr(charFilesName); 
  
  
%Set the duration of the for loop by the number of patients in the 
selected 
%directory 
ptcnt=size(FileName, 1); 
  
  148 
%Create data matrix 
Ptdata=[]; 
  
%Read file and extract DICOM tags 
for i=1:ptcnt    
     
    %Filter to skip files without the .dcm file extension 
    TempFile=FileName{i}; 
     
    %Checks the files for the .dcm extension, if not .dcm exits loop 
and 
    %moves to the next file in the list 
    if length(TempFile)> 4 
        if ~isequal(TempFile(end-3:end), '.dcm') 
            continue; 
        end 
    else 
        continue; 
    end 
     
    %Writest the dicom header to a cell array 
    img =[PathName, '\', FileName{i}];     
    info = dicominfo (img, 'dictionary','DicomDict_Plan.txt'); 
     
    %Determines if the header is from a PET image, ie 
Radiopharmecuticals, 
    %if not, sets those fields as zero 
    if isfield(info, 'RadiopharmaceuticalInformationSequence') && 
ischar('RadiopharmaceuticalInformationSequence.Item_1.Radiopharmaceutic
alStartTime')&& 
ischar('RadiopharmaceuticalInformationSequence.Item_1.RadionuclideTotal
Dose'); 
        Ptx = 
[str2num(info.PatientID),str2num(info.StudyDate),info.PatientSize, 
info.PatientWeight,info.SliceThickness,... 
            
str2num(info.SoftwareVersion),info.ReconstructionDiameter,info.PixelSpa
cing(1),info.RescaleSlope,... 
            str2num(info.AcquisitionTime),str2num(info.SeriesTime),... 
            
str2num(info.RadiopharmaceuticalInformationSequence.Item_1.Radiopharmac
euticalStartTime),... 
            
info.RadiopharmaceuticalInformationSequence.Item_1.RadionuclideTotalDos
e,{info.ManufacturerModelName},{info.CorrectedImage}]; 
    else 
        Ptx = 
[str2num(info.PatientID),str2num(info.StudyDate),info.PatientSize, 
info.PatientWeight,info.SliceThickness,... 
            
str2num(info.SoftwareVersion),info.ReconstructionDiameter,info.PixelSpa
cing(1),info.RescaleSlope,... 
            
str2num(info.AcquisitionTime),str2num(info.SeriesTime),0,0,0,0]; 
    end 
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    %Writes tags to a matrix 
    Ptdata=[Ptdata; Ptx]; 
end 
  
%Character array that is written to excel file as label for data 
hdr = {'MRN','Date', 'Patient Height (m)', 'Patient Weight (kg)', 
'Slice Thickness (cm)','Software Version','Recon Diameter (mm)','Pixel 
Spacing (mm)',... 
            'Rescale Slope','Acquisition Time (HHMMSS)','Series Time 
(HHMMSS)','RadioPharm Start Time (HHMMSS)','Dose (Bq)','Model 
Name','Applied Corrections'}; 
  
%Write patient data matrix to excel file 
d = datestr(now,30); 
xlswrite([PathName,'\','Header Data','_',d,'.xls'],hdr,'Header Data'); 
xlswrite([PathName,'\','Header Data','_',d,'.xls'],Ptdata,'Header 
Data','A2'); 
 
PETThreshold 
 The following script is designed for use with the Pinnacle3 treatment 
planning system to create threshold contours on PET images.  
// Recalculate stats for max pixel 
RoiList.# "Max Pixel".RecomputeStatistics=""; 
 
// Autocontour 50% threshold 
Store.FloatAt.Fifty = RoiList.# "Max Pixel".MaxDisplay; 
Store.At.Fifty.Multiply=0.5; 
RoiList.# "50Primary".AutoLower = Store.At.Fifty.Value; 
RoiList.# "50Primary".MakeCurrent=""; 
RoiList .# "50Primary".AutoContourROI = "Current Region Of Interest"; 
Store.FreeAt.Fifty=""; 
 
// Change 50% threshold data set to CT 
Store.StringAt.CTdata = RoiList.# "C2".VolumeName; 
RoiList.# "50Primary".VolumeName = CTdata; 
 
// Cleanup ROI 
RoiList .Current .Clean = "Rescan"; 
RoiList .Current .CleanAndDelete = "Delete Curves"; 
 
//Eliminate all autocontours in head 
RoiExpandControl.SourceRoiList.Current.Remove=""; 
RoiExpandControl.AvoidRoiList.Current.Remove=""; 
RoiExpandControl.TargetRoi.Remove=""; 
RoiList.Current="50Primary"; 
RoiExpandControl .AddSourceRoi = "Add -->"; 
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RoiList .Current = "Head"; 
RoiExpandControl .AddAvoidRoi = "Add -->"; 
RoiExpandControl .Expand = 0; 
RoiExpandControl .TargetRoi = "na"; 
RoiExpandControl .DoExpand = "Proceed"; 
 
// Remove curves from 50Primaryrimary 
RoiList.Current="50Primary"; 
RoiList.Current.RemoveAllCurves = ""; 
Test.ExpectAskYesNo = 1; 
 
 
//Move 50% threshold curves from NA back to 50Primary 
RoiExpandControl.SourceRoiList.Current.Remove=""; 
RoiExpandControl.AvoidRoiList.Current.Remove=""; 
RoiExpandControl.TargetRoi.Remove=""; 
RoiList .Current = "na"; 
RoiExpandControl .AddSourceRoi = "Add -->"; 
RoiExpandControl .Expand = 1; 
RoiExpandControl .TargetRoi = "50Primary"; 
RoiExpandControl .DoExpand = "Proceed"; 
 
// Remove curves from NA 
RoiList .Current = "na"; 
RoiList.Current.RemoveAllCurves = ""; 
Test.ExpectAskYesNo = 1; 
 
petctfusion 
 The following script is a command line fusion image viewer designed for 
use with CT images and compressed PET images in the *.txtimg format.  Of 
particular importance is the DualMap.m script for combined colorbars 
function [RTstruct RTalphamap AxialImage, CTmax, CTrange,path,file] = 
petctfusion(x) 
  
%The following script will create a dual color map PET/CT figure.  The 
CT 
%image set should be a reference and the PET overlay should be an ROI.  
The 
%input should be the slice number. 
  
%Select the reference image set 
[Xpixels, Ypixels, ZsliceNum, AxialImage] = OpenPinnacleImages; 
%Select the overlay structure 
[RTstruct,path,file] = OverlayImg(Xpixels,Ypixels,ZsliceNum); 
%Perform a hard W/L on the reference CT images 
[AxialImage,CTmax,CTrange] = SoftTissue(AxialImage); 
%Create the aplha map to determine opacity of the overlay image 
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RTalphamap=RTalpha(RTstruct); 
%Create the figure with a dual color map 
DualMap(AxialImage, RTstruct,x,RTalphamap,CTmax,CTrange); 
 
OpenPinnacleImages 
 The following script was utilized to open binary format images compatible 
with the Pinnacle3 treatment planning system. 
function [Xpixels, Ypixels, ZsliceNum, AxialImage] = 
OpenPinnacleImages(hdr) 
  
  
if isdir(['G:\Research\Head and Neck\H&N PET_CT deformable 
registration\'... 
        'Data and Analysis\Data\']); 
  
    [file path FilterIndex]=uigetfile('*.header','Select image header 
file.',... 
        ['G:\Research\Head and Neck\H&N PET_CT deformable 
registration\'... 
        'Data and Analysis\Data\']); 
    hdr = [path file]; 
    imfile = [file(1:end-6) 'img']; 
else 
    [file path]=uigetfile('*.header','Select image header file.'); 
    hdr = [path file]; 
    imfile = [file(1:end-6) 'img']; 
end 
  
  
%The following function will open Pinnacle CT images 
HeaderInfo=textread(hdr, '%s', 'delimiter', '\n'); 
a=char(39); 
HeaderInfo = regexprep(HeaderInfo, '"', a); 
  
%Get Byte order, actual operation 
for kk=1:20 
    eval(HeaderInfo{kk}); 
end 
  
Xpixels=x_dim; 
Ypixels=y_dim; 
ZsliceNum=z_dim; 
  
%Read daily pinnalce data 
if byte_order == 0 
    fid=fopen([path imfile], 'r', 'ieee-le'); 
else 
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    fid=fopen([path imfile], 'r', 'ieee-be'); 
end 
  
  
[TempData, Count]=fread(fid, Xpixels*Ypixels*ZsliceNum, '*int16'); 
TempData=uint16(TempData); 
fclose(fid); 
  
AxialImage=reshape(TempData, [Xpixels, Ypixels, ZsliceNum]); 
AxialImage=permute(AxialImage, [2,1, 3]); 
 
OverlayImg 
 The following code will turn the compressed image files in the *.txtimg 
format into false color images that can be fused with grayscale CT images. 
function [RTstruct,path,file] = OverlayImg(Xpixels,Ypixels,ZsliceNum) 
  
%This code will turn the *.txtimg files into useable images based upon 
%outputs from the OpenPinnacleImages function 
  
if isdir(['C:\Documents and Settings\bacannon\My 
Documents\Research\']); 
  
    [file path FilterIndex]=uigetfile('*.txtimg','Select text image 
file.',... 
        ['C:\Documents and Settings\bacannon\My Documents\Research\']); 
    img = [path file]; 
    %imfile = [file(1:end-6) 'img']; 
else 
    [file path]=uigetfile('*.txtimg','Select text image file.'); 
    img = [path file]; 
    %imfile = [file(1:end-6) 'img']; 
end 
  
fid = fopen(img,'r'); 
%The following function will open the text image file 
Temp = textscan(fid,'%-15.0f%-15.0f%-15.0f%-15.4f%-15.4f%-15.4f%-
15.4f'); 
ImgData = [Temp{1},Temp{2},Temp{3},Temp{4},Temp{5},Temp{6},Temp{7}]; 
clear Temp; 
fclose(fid); 
  
%Create the empty matrix that will be the image 
RTstruct = zeros (Xpixels, Ypixels, ZsliceNum); 
%Determine the indcies for the data in the volumetric data set 
IND = sub2ind(size(RTstruct),ImgData(:,2),ImgData(:,1),ImgData(:,3)); 
  
%Place value of interest as pixel value 
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    %Column 1 - 3: x, y, and z location 
    %Column 4: Fractional uptake 
    %Column 5: Mean metabolic dose 
    %Column 6: Mean SUV1 
    %Column 7: Mean SUV2 
    %By changing the data one must alter line 55 of DualMap.m 
RTstruct(IND) = ImgData(:,6); 
  
clear IND ImgData 
  
 
SoftTissue 
 The following script will perform a hard window/level operation to set the 
dynamic range of CT images to a soft tissue window. 
function [AxialImage,CTmax,CTrange] = SoftTissue(AxialImage) 
  
%This function will rescale the CT data to be in the soft tissue window 
%range 
CTmax = int16(1200); 
CTrange = int16(400); 
X = size(AxialImage,1); 
Y = size(AxialImage,2); 
Z = size(AxialImage,3); 
  
%Rescal the CT image to the soft tissue window 
for i=1:(X*Y*Z) 
    if AxialImage(i) < 800; 
        AxialImage(i)=800; 
    elseif AxialImage(i) > 1200; 
        AxialImage(i)=1200; 
    else 
    end 
end 
  
 
RTalpha 
 The code given below was utilized to create an opacity mask for the 
overlay images. 
function RTalphamap=RTalpha(RTstruct) 
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X = size(RTstruct,1); 
Y = size(RTstruct,2); 
Z = size(RTstruct,3); 
RTalphamap = zeros (X,Y,Z); 
  
for i=1:(X*Y*Z) 
    if RTstruct(i)==0 
        RTalphamap(i)= 0; 
    else 
        RTalphamap(i)=1; 
    end 
end 
 
DualMap 
 The following script is the most critical for image overlay in the MATLAB 
workspace.   
function DualMap(AxialImage, RTstruct,x,RTalphamap,CTmax,CTrange) 
  
%The following script will create a dual color map image with fused 
%AxialImage and overlay RTstruct 
  
%Create the figure 
hf = figure('units','normalized','position',[.2 .2 .6 
.6],'Color','none'); 
%Assign bg image to im1 
im1=AxialImage(:,:,x); 
%Assign fg image to im2 
im2=RTstruct(:,:,x); 
  
%Open the image 
hax1 = imagesc(im1); 
%Set the aspect ratio 
axis('image') 
axis off 
hold on 
  
%Set the colormap for the bg as grayscale 
cmap1 = colormap(gray); 
ax1 = gca; 
set(ax1,'Color','none') 
%Set the fg axes 
ax2 =axes('Position',get(ax1,'Position')); 
%Open the fg images and get its handle 
hax2 = imagesc(im2); 
%Set the aspect ratio  
axis('image') 
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axis off 
%Overlay the ax2 ontop of ax1 
set(ax2,'YAxisLocation','right','Color','none','XTickLabel',[]); 
set(ax2,'XLim',get(ax1,'XLim'),'Layer','top') 
  
%Set the cololmap for the fg image as jet 
cmap2=colormap(jet); 
%Splice the two colormaps into one 
colormap([cmap1;cmap2]); 
%Determine the length of the entire colormap 
CmLength   = length(colormap); 
%Set the beginning position of the colormap 
BeginSlot1 = 1; 
%Set the end position of the first colormap scale 
EndSlot1   = length(cmap1); 
%Set the beginning position of the second colormap scale 
BeginSlot2 = EndSlot1 + 1; 
%Set the end position of the second colormapr scale 
EndSlot2   = CmLength; 
%Determine the current color limits for the bg image 
CLim1 = [min(min(min(AxialImage))) max(max(max(AxialImage)))]; 
%Determine the current color limits for the fg image 
%CLim2 = [min(min(min(RTstruct))) max(max(max(RTstruct)))]; 
  
%Set the CLim2 for presentation plots, same scale 
CLim2 = [.4 2.0]; 
  
%Set the color limits for the bg image 
set(ax1,'CLim',newclim(BeginSlot1,EndSlot1,CLim1(1),... 
        CLim1(2),CmLength)); 
%Set the color limits for the fg image 
set(ax2,'CLim',newclim(BeginSlot2,EndSlot2,CLim2(1),... 
        CLim2(2),CmLength)); 
%Set the transparency 
set(hax2, 'AlphaData',RTalphamap(:,:,x)); 
%Set the position of the color 
cbar_axes = colorbar('Position',[.835 .11 .062 .815]); 
%Set the CT label for the colorbar 
Ylabel = str2num(get(cbar_axes,'YTickLabel')); 
f=int16(1); 
if rem(size(Ylabel,1),2)==1 
    %Number of labels 
    LabCnt = int16(round(size(Ylabel,1)/2)-1); 
    %The colorbar has an odd number of labels 
    for i=LabCnt:-1:1 
        Ylabel(i,1)= CTmax - (CTrange/LabCnt)*f; 
        f=f+1; 
    end 
else 
    %Number of labels 
    LabCnt = int16(size(Ylabel,1)/2); 
    %The colorbar has an even number of labels 
    for i=LabCnt:-1:1 
    Ylabel(i,1) = CTmax - (CTrange/(LabCnt+1))*f; 
    f=f+1; 
    end 
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end 
set(cbar_axes,'YTickLabel',num2str(Ylabel),'YColor',[.968 .968 .968]); 
  
  
  
Metabolic Dose 
The following script was utilized to construct voxel based dose-metabolic 
response curve. 
 
function MetabolicDose_Batch(PtData, PtName, PathName, drun, Norm) 
  
%%!!!!!!!  MUST!!! be used with Main_Head_Batch.m or define the golobal 
%%                                  varibles below!!!!!! 
  
%The following algorithm will create a dose-uptake response curve for 
the 
%sturctures contained within the *.roi file based upon the metabolic 
dose 
%metric.  Bins are created by binning the dose to achieve uniformity 
and 
%the computing the metabolic dose metric and fractional uptake for said 
%regions. 
  
%Define the type of analysis 
%BinType = 1 - Dose binned analysis 
%BinTpye = 2 - Function binned analysis 
%BinType = 3 - Metabolic dose binned analysis 
BinType = 3; 
SumFlag = 0; 
if isdir([PathName,'\','MetabolicDoseBin_data']) 
    d = datestr(now,30); 
    mkdir(PathName,['MetabolicDoseBin_data_',d]); 
    mkdir(PathName,['MetabolicDoseBin_plot_',d]); 
    mkdir(PathName,['MetabolicDoseBin_txtimg_',d]); 
    dataWritePath = [PathName,'\','MetabolicDoseBin_data_',d]; 
    plotWritePath = [PathName,'\','MetabolicDoseBin_plot_',d]; 
    txtimgWritePath = [PathName,'\','MetabolicDoseBin_txtimg_',d]; 
else 
    mkdir(PathName,'MetabolicDoseBin_data'); 
    mkdir(PathName,'MetabolicDoseBin_plot'); 
    mkdir(PathName,'MetabolicDoseBin_txtimg'); 
    dataWritePath = [PathName,'\','MetabolicDoseBin_data']; 
    plotWritePath = [PathName,'\','MetabolicDoseBin_plot']; 
    txtimgWritePath = [PathName,'\','MetabolicDoseBin_txtimg']; 
end 
  
%Define the header string that all files will use in this function 
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HeaderStr={'Patient:  '; ... 
    'Dose_min(cGy)'; ... 
    'Dose_max(cGy)'; ... 
    'Dose_mean(cGy)'; ... 
    'Dose_std(cGy)'; ... 
    'SUV1_min'; ... 
    'SUV1_max'; ... 
    'SUV1_mean'; ... 
    'SUV1_std'; ... 
    'SUV2_min'; ... 
    'SUV2_max'; ... 
    'SUV2_mean'; ... 
    'SUV2_std'; ... 
    'Metabolic_Dose_min(cGyMBq/mL)'; ... 
    'Metabolic_Dose_max(cGyMBq/mL)'; ... 
    'Metabolic_Dose_mean(cGyMBq/mL)'; ... 
    'Metabolic_Dose_median(cGyMBq/mL)'; ... 
    'Metabolic_Dose_std(cGyMBq/mL)'; ... 
    'Lilliefors_MetabolicDose';... 
    'Kurtosis_MetabolicDose';... 
    'Skewness_MetabolicDose';... 
    'Fractional_Uptake_min'; ... 
    'Fractional_Uptake_max'; ... 
    'Fractional_Uptake_mean'; ... 
    'Fractional_Uptake_std'; ... 
    'Lilliefors_FractionalUptake';... 
    'Kurtosis_FractionalUptake';... 
    'Skewness_FractionalUptake';... 
    'VolumeFraction';... 
    'VoxelCount'}; 
  
%This code will cause problems if not used with Main_Head_Batch 
TempIndex=strmatch('Patient:  ', HeaderStr); 
HeaderStr{TempIndex}=['Patient:  ', PtName]; 
  
%Gather all ROIs present in PtData structure 
FieldNames=fieldnames(PtData); 
  
  
for j=1:length(FieldNames) 
    %disp([PtName,' ',FieldNames{j}]) 
    tempFieldName = FieldNames{j}; 
    %Sort the ROI by physical dose 
    PtData.(FieldNames{j}) = sortrows(PtData.(FieldNames{j}),4); 
    %Identify voxels that received less than 500 cGy 
    DoseFilter = find(PtData.(FieldNames{j})(:,4)<500); 
    %Remove voxels receiving less than 500 cGy from analysis 
    PtData.(FieldNames{j})(DoseFilter(:,1),:) = []; 
    %If all physical dose is below threshold, do not analyze 
    if isempty(PtData.(FieldNames{j})); 
        continue; 
    end 
    %Compute the Metabolic dose metric for each voxel 
    PtData.(FieldNames{j})(:,8) = 
PtData.(FieldNames{j})(:,4).*PtData.(FieldNames{j})(:,5);     
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    if 
(strcmp(tempFieldName,'ROIGTVprimary')||strcmp(tempFieldName,'ROI40Prim
ary')||... 
            
strcmp(tempFieldName,'ROI50Primary')||strcmp(tempFieldName,'ROI40PAirlm
td')||... 
            
strcmp(tempFieldName,'ROI50PAirlmtd')||strcmp(tempFieldName,'ROI40Node'
)||... 
            
strcmp(tempFieldName,'ROI50Node')||strcmp(tempFieldName,'ROI40NAirlmtd'
)||... 
            
strcmp(tempFieldName,'ROI50NAirlmtd')||strcmp(tempFieldName,'ROIGTVAirl
mtd')||... 
            
strcmp(tempFieldName,'ROIGTVNodesAir')||strcmp(tempFieldName,'ROIGTVnod
e')||... 
            strcmp(tempFieldName,'ROIRefBrainstem')); 
  
        continue;     
        if ((max (PtData.(FieldNames{j})(:,8)) - min 
(PtData.(FieldNames{j})(:,8)))>100000);             
            DoseBin = (min (PtData.(FieldNames{j})(:,8)):10000:max 
(PtData.(FieldNames{j})(:,8))); 
        else 
            DoseBin = (min (PtData.(FieldNames{j})(:,8)):2000:max 
(PtData.(FieldNames{j})(:,8))); 
        end 
    elseif  
(strcmp(tempFieldName,'ROIParotidR')||strcmp(tempFieldName,'ROIParotidL
')||... 
            
strcmp(tempFieldName,'ROIIpsilateralParotid')||strcmp(tempFieldName,'RO
IContralateralParotid')||... 
            
strcmp(tempFieldName,'ROIParotids')||strcmp(tempFieldName,'ROISMG')) 
            DoseBin = (min (PtData.(FieldNames{j})(:,8)):2000:max 
(PtData.(FieldNames{j})(:,8))); 
    else 
        continue; 
        if strcmp(tempFieldName,'ROI70Gy') 
                if ((max (PtData.(FieldNames{j})(:,8)) - min 
(PtData.(FieldNames{j})(:,8)))>100000); 
                    DoseBin = (min 
(PtData.(FieldNames{j})(:,8)):10000:max (PtData.(FieldNames{j})(:,8))); 
                else 
                    DoseBin = (min 
(PtData.(FieldNames{j})(:,8)):2000:max (PtData.(FieldNames{j})(:,8))); 
                end 
            else 
                continue; 
            end 
%         if ((max (PtData.(FieldNames{j})(:,8)) - min 
(PtData.(FieldNames{j})(:,8)))<500) 
%             %Dose bin size set at 10 cGy 
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%             DoseBin = (min (PtData.(FieldNames{j})(:,8)):10:max 
(PtData.(FieldNames{j})(:,8))); 
%         %elseif ((max (PtData.(FieldNames{j})(:,8)) - min 
(PtData.(FieldNames{j})(:,8)))>) 
%         else 
%             %Dose bin size set at 500 cGy 
%             DoseBin = (min (PtData.(FieldNames{j})(:,8)):500:max 
(PtData.(FieldNames{j})(:,8))); 
%         end 
    end 
  
    %Create the dose bin label i.e., make the bins integers and 
eliminate 
    %trailing and leading zeros 
    DoseName = strtrim(cellstr(num2str(uint32(DoseBin')))); 
    %Compute the total number of pixels in the ROI for fractional 
volume 
    %purposes 
    VolumeTotal = size(PtData.(FieldNames{j}),1); 
  
    %Open the text file for writing fDVH data 
    fid = fopen([dataWritePath,'\', FieldNames{j},'.out'],'wt'); 
  
    if 
(strcmp(tempFieldName,'ROIGTVprimary')||strcmp(tempFieldName,'ROI40Prim
ary')||... 
            
strcmp(tempFieldName,'ROI50Primary')||strcmp(tempFieldName,'ROI40PAirlm
td')||... 
            
strcmp(tempFieldName,'ROI50PAirlmtd')||strcmp(tempFieldName,'ROIGTVAirl
mtd')||... 
            
strcmp(tempFieldName,'ROIContralateralParotid')||strcmp(tempFieldName,'
ROIIpsilateralParotid')||... 
            
strcmp(tempFieldName,'ROIParotidR')||strcmp(tempFieldName,'ROIParotidL'
)||... 
            strcmp(tempFieldName,'ROIParotids')); 
         
        %Open file for writing text image data 
        fid2 = fopen([txtimgWritePath,'\', 
tempFieldName,'.txtimg'],'wt'); 
    end 
     
    %Write the header to text file 
    for k=1:length(HeaderStr) 
        if k == 1 
            fprintf(fid, '%-35s\n\n', HeaderStr{k}); 
        elseif k == (length(HeaderStr)) 
            fprintf(fid, '%-35s\n', HeaderStr{k}); 
        else 
            fprintf(fid, '%-35s', HeaderStr{k}); 
        end 
    end 
    %Initialize the text image matrix 
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    ImgTxtData = []; 
    BinData = zeros(29,size(DoseBin,2)); 
    for i=1:(size(DoseBin,2)); 
        MetDose = []; 
        %Identify indecies of data falling into volume-dose bins 
        if i == size(DoseBin,2); 
            %Finds indicies for the last dose bin 
            PtHisto.(FieldNames{j}).DoseBin{i} = 
find((PtData.(FieldNames{j})(:,8) >= DoseBin(i))); 
        else 
            %Finds indicies for all bins except last bin 
            PtHisto.(FieldNames{j}).DoseBin{i} = 
find((PtData.(FieldNames{j})(:,8) >= DoseBin(i)) & 
(PtData.(FieldNames{j})(:,8) < DoseBin(i+1))); 
        end 
  
        %Extract the needed data to individual volume-dose bins 
        PtHisto.(FieldNames{j}).data.(['V' DoseName{i}]) = 
PtData.(FieldNames{j})(PtHisto.(FieldNames{j}).DoseBin{1,i},:); 
        %If the dose bin is empty, simply set datum as NaN 
        if isempty(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,7)); 
            BinData(1:29,i) = NaN; 
            continue; 
        elseif size(PtHisto.(FieldNames{j}).data.(['V' DoseName{i}]),1) 
< 4; 
            %Write the Dose data to matrix 
            BinData(1,i) = min(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,4)); 
            BinData(2,i) = max(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,4)); 
            BinData(3,i) = mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,4)); 
            BinData(4,i) = std(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,4)); 
            %Write SUV1 data to matrix 
            BinData(5,i) = min(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5)); 
            BinData(6,i) = max(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5)); 
            BinData(7,i) = mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5)); 
            BinData(8,i) = std(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5)); 
            %Write SUV2 data to matrix 
            BinData(9,i) = min(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,6)); 
            BinData(10,i) = max(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,6)); 
            BinData(11,i) = mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,6)); 
            BinData(12,i) = std(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,6)); 
            %Write Metabolic Dose data to matrix 
            MetDose = PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,4) .* ...; 
                PtHisto.(FieldNames{j}).data.(['V' DoseName{i}])(:,5); 
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            BinData(13,i) = min(MetDose); 
            BinData(14,i) = max(MetDose); 
            BinData(15,i) = mean(MetDose); 
            BinData(16,i) = median(MetDose); 
            BinData(17,i) = 
((mean(MetDose)^2)*((var(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5))/...; 
                (mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5)))^2)+...; 
                (var(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,4))/...; 
                (mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,4)))^2)))^0.5; 
            %Do not perform Lilliefors 
            BinData(18,i) = NaN; 
            %Do not perform Kurtosis 
            BinData(19,i) = NaN; 
            %Do not perform Skewness 
            BinData(20,i) = NaN;             
            %Write Fractional Uptake data to matrix 
            BinData(21,i) = min(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,7)); 
            BinData(22,i) = max(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,7)); 
            BinData(23,i) = mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,7));            
            %Write the std of F.U., using propagation of error with 
            %correlated data term 
            FU = cov(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5),... 
                PtHisto.(FieldNames{j}).data.(['V' DoseName{i}])(:,6)); 
            BinData(24,i) = ((mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,7)))^2*... 
                ((var(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5))/... 
                (mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5)))^2)+... 
                ((var(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,6)))/... 
                (mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,6)))^2)-... 
                (2*FU(1,2)/(mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5))*... 
                mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,6))))))^0.5;      
            %Do not perform Lilliefors 
            BinData(25,i) = NaN; 
            %Do not perform Kurtosis 
            BinData(26,i) = NaN; 
            %Do not perform Skewness 
            BinData(27,i) = NaN;   
            %Write fractional volume of current bin to matrix 
            BinData(28,i) = size(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}]),1)/VolumeTotal; 
            %Write number of voxels of current bin to matrix 
            BinData(29,i) = size(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}]),1); 
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            %Do not perform tests for normality of bin 
                       
        else 
             %Write the Dose data to matrix 
            BinData(1,i) = min(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,4)); 
            BinData(2,i) = max(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,4)); 
            BinData(3,i) = mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,4)); 
            BinData(4,i) = std(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,4)); 
            %Write SUV1 data to matrix 
            BinData(5,i) = min(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5)); 
            BinData(6,i) = max(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5)); 
            BinData(7,i) = mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5)); 
            BinData(8,i) = std(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5)); 
            %Write SUV2 data to matrix 
            BinData(9,i) = min(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,6)); 
            BinData(10,i) = max(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,6)); 
            BinData(11,i) = mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,6)); 
            BinData(12,i) = std(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,6)); 
            %Write Metabolic Dose data to matrix 
            MetDose = PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,4) .* ...; 
                PtHisto.(FieldNames{j}).data.(['V' DoseName{i}])(:,5); 
            BinData(13,i) = min(MetDose); 
            BinData(14,i) = max(MetDose); 
            BinData(15,i) = mean(MetDose); 
            BinData(16,i) = median(MetDose); 
            BinData(17,i) = 
(mean(MetDose)^2*((var(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5))/... 
                (mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5)))^2)+... 
                (var(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,4))/... 
                (mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,4)))^2)))^0.5; 
            %Perform Lilliefors test for goodness of fit to normal 
            %distribution to metabolic dose data 
            BinData(18,i) = lillietest(MetDose); 
            %Determine sample kurtosis, normal = 3, more outlier 
prone>3, 
            %less outlier prone<3 for metabolic dose data 
            BinData(19,i) = kurtosis(MetDose); 
            %Determine sample skewness, if negative data are spread to 
left 
            %of mean, if positive data are to right of mean, zero is 
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            %symmetric distribution 
            BinData(20,i) = skewness(MetDose);  
            %Write Fractional Uptake data to matrix 
            BinData(21,i) = min(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,7)); 
            BinData(22,i) = max(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,7)); 
            BinData(23,i) = mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,7)); 
            %Write the std of F.U., using propagation of error with 
            %correlated data term 
            FU = cov(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5),... 
                PtHisto.(FieldNames{j}).data.(['V' DoseName{i}])(:,6)); 
            BinData(24,i) = ((mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,7)))^2*... 
                ((var(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5))/... 
                (mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5)))^2)+... 
                ((var(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,6)))/... 
                (mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,6)))^2)-... 
                (2*FU(1,2)/(mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,5))*... 
                mean(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,6))))))^0.5;             
            %Perform Lilliefors test for goodness of fit to normal 
            %distribution 
            BinData(25,i) = 
lillietest(PtHisto.(FieldNames{j}).data.(['V' DoseName{i}])(:,7)); 
            %Determine sample kurtosis, normal = 3, more outlier 
prone>3, 
            %less outlier prone<3 
            BinData(26,i) = kurtosis(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,7)); 
            %Determine sample skewness, if negative data are spread to 
left 
            %of mean, if positive data are to right of mean, zero is 
            %symmetric distribution 
            BinData(27,i) = skewness(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,7));   
            %Write fractional volume of current bin to matrix 
            BinData(28,i) = size(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}]),1)/VolumeTotal; 
            %Write number of voxels of current bin to matrix 
            BinData(29,i) = size(PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}]),1); 
        end 
        if 
(strcmp(tempFieldName,'ROIGTVprimary')||strcmp(tempFieldName,'ROI40Prim
ary')||... 
                
strcmp(tempFieldName,'ROI50Primary')||strcmp(tempFieldName,'ROI40PAirlm
td')||... 
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strcmp(tempFieldName,'ROI50PAirlmtd')||strcmp(tempFieldName,'ROIGTVAirl
mtd')||... 
                
strcmp(tempFieldName,'ROIContralateralParotid')||strcmp(tempFieldName,'
ROIIpsilateralParotid')||... 
                
strcmp(tempFieldName,'ROIParotidR')||strcmp(tempFieldName,'ROIParotidL'
)||... 
                strcmp(tempFieldName,'ROIParotids')); 
             
            tempMetDoseName = 
char(strtrim(cellstr(num2str(uint32(BinData(15,i)))))); 
            tempFracUptkName = 
char(strtrim(cellstr(num2str(uint32(BinData(23,i)))))); 
            tempdosename = char(DoseName(i)); 
            %Create histogram of dose bin 
            SubPlothisto(tempFieldName, tempMetDoseName, 
tempFracUptkName, tempdosename, PtHisto, plotWritePath, MetDose, Norm, 
SumFlag); 
            clear tempdosename  tempMetDoseName  tempFracUptkName FU 
            %Create temporary matrix of current dose bin's x, y, and z 
indicies 
            tempTxtData = (PtHisto.(FieldNames{j}).data.(['V' 
DoseName{i}])(:,1:3))'; 
            %Place the dose bin's mean fractional uptake as the pixel 
value 
            tempTxtData(4,:) = BinData(23,i); 
            %Place the mean metabolic dose for this region 
            tempTxtData(5,:) = BinData(15,i); 
            %Place the mean SUV1 for this region 
            tempTxtData(6,:) = BinData(7,i); 
            %Place the mean SUV2 for this region 
            tempTxtData(7,:) = BinData(11,i); 
            %Write image data to text file 
            fprintf(fid2, '%-15.0f%-15.0f%-15.0f%-15.4f%-15.4f%-15.4f%-
15.4f\n', tempTxtData); 
            tempTxtData=[]; 
        end 
    end 
    %Eliminate the NaNs from the BinData matrix 
    EmptyBinIndex = isnan(BinData(1,:));     
    BinData(:,EmptyBinIndex) = [];     
    %Write fDVH plot to file calling subfunction 
    SubPlotfDVH(tempFieldName, BinData, plotWritePath, Norm, BinType); 
    %Write differential dose volume histogram 
    SubPlotdiffDVH(tempFieldName, BinData, plotWritePath, Norm, 
BinType); 
    %Write cummulative dose volume histogram 
    SubPlotcummDVH(tempFieldName, BinData, plotWritePath, Norm, 
BinType); 
    if 
(strcmp(tempFieldName,'ROIGTVprimary')||strcmp(tempFieldName,'ROI40Prim
ary')||... 
            
strcmp(tempFieldName,'ROI50Primary')||strcmp(tempFieldName,'ROI40PAirlm
td')||... 
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strcmp(tempFieldName,'ROI50PAirlmtd')||strcmp(tempFieldName,'ROIGTVAirl
mtd')||... 
            
strcmp(tempFieldName,'ROIContralateralParotid')||strcmp(tempFieldName,'
ROIIpsilateralParotid')||... 
            
strcmp(tempFieldName,'ROIParotidR')||strcmp(tempFieldName,'ROIParotidL'
)||... 
            strcmp(tempFieldName,'ROIParotids')); 
         
        %Close the text image 
        fclose(fid2); 
    end 
    %Write the BinData matrix to 
    fprintf(fid,'%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-
35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-
35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-35.4f%-
35.4f%-35.4f\n',BinData); 
    fclose(fid); 
    %Write data to summary file for entire patient cohort 
    summaryfile(tempFieldName, BinData, PathName, drun, PtName, 
BinType,PtData); 
    %Write unbinned data to summary file for entire cohort 
    %Unbinnedsummaryfile(tempFieldName, PtData, PathName, drun, PtName, 
BinType); 
    clear PtHisto DoseBin DoseName VolumeTotal BinData tempFieldName 
tempTxtData; 
end 
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